

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 477 739 A2

(12)

EUROPEAN PATENT APPLICATION(21) Application number: **91115787.3**

(51) Int. Cl.⁵: **C12N 15/55, C12N 9/16,
C12P 21/02, C12P 21/08,
A61K 39/395**

(22) Date of filing: **18.09.91**(30) Priority: **27.09.90 US 588896**

(43) Date of publication of application:
01.04.92 Bulletin 92/14

(84) Designated Contracting States:
AT BE CH DE DK FR GB IT LI NL

(71) Applicant: **F. HOFFMANN-LA ROCHE AG
Postfach 3255
CH-4002 Basel(CH)**

(72) Inventor: **Huang, Kuo-Sen
38 Intervale Road
Livingston, N.J. 70039(US)
Inventor: Kochan, Jarema Peter
7 Crestmont Road
Verona, N.J. 07044(US)
Inventor: Li, Shirley Hsia-Han
969 Bloomfield Avenue
Glen Ridge, N.J. 07028(US)
Inventor: Pan, Yu-Ching Eugene
10 Crane Drive
Pine Brook, N.J. 07058(US)
Inventor: Scallon, Bernard James
500 Center Street
Nutley, N.J. 07110(US)
Inventor: Tsang, Thomas Christopher
Hin-Sing
468 De Witt Avenue
Belleville, N.J. 07109(US)**

(74) Representative: **Mezger, Wolfgang, Dr. et al
Grenzacherstrasse 124 Postfach 3255
CH-4002 Basel(CH)**

(54) **Glycosyl-Phosphatidylinositol-Specific Phospholipase D.**

(57) The present invention relates to the protein glycosyl phosphatidylinositol-specific phospholipase D (GPI-PLD) in a substantially pure form, an polynucleotide coding for GPI-PLD, vectors containing the isolated polynucleotide coding for GPI-PLD, and cells transformed by a vector containing the polynucleotide coding for GPI-PLD. Also described is a method for producing a protein which can be secreted from a eukaryotic cell comprising co-transfecting a eukaryotic cell with a gene encoding a glycosyl phosphatidylinositol-anchored protein with glycosyl phosphatidylinositol-specific phospholipase D.

EP 0 477 739 A2

The present invention lies in the fields of protein, recombinant DNA and genetic engineering.

Recent studies have revealed that a growing number of cell surface proteins are attached to the membrane by covalent linkage to a glycosylphosphatidylinositol (GPI) anchor. The physiological role played by this new class of membrane anchor is unknown, but one possibility is that it facilitates the release of molecules by specific phospholipases in vivo.

Several mammalian phospholipase activities which seem to be capable of removing the GPI anchors from proteins have been reported. These were originally attributed to the action of a phosphatidylinositol (PI)-specific phospholipase C since enzymes of this specificity are widely distributed in mammalian tissues. However, the physiological significance of such a process remained in question because almost all of the mammalian PI-specific phospholipase C's are believed to be intracellular in location whereas the GPI-anchored proteins are found on the cell surface. Subsequently, it was shown that inhibition of placental PI-specific phospholipase C activity does not affect GPI-anchor degrading activity, indicating that other enzymes are responsible for the release of GPI-anchored proteins. It was therefore suggested that this activity was due to a novel phospholipase D with specificity for the GPI-anchor. Recently, several groups have reported the presence of high levels of a GPI-specific phospholipase D (GPI-PLD) in mammalian plasma and serum [Low, M. G., and Prasad, A. R. S. (1988) *Proc. Natl. Acad. Sci. USA*, 85, 980-984; Davitz, M. A., Hereld, D., Shak, S., Krakow, J., Englund, P. L., and Nussenzweig, V. (1987) *Science*, 238, 81-84; Cardoso de Almeida, M. L., Turner, M. J., Stambuk, B. B. and Schenkman, S. (1988) *Biochem. Biophys. Res. Commun.*, 150, 476-482]. Because of its extracellular location and specificity for GPI, this enzyme may be responsible for releasing GPI-anchored proteins from cell surfaces in vivo.

The present invention relates to the protein glycosyl phosphatidylinositol-specific phospholipase D (GPI-PLD) or biologically active fragments thereof substantially free from other proteins, polynucleotides encoding GPI-PLD or biologically active fragments thereof, vectors containing a polynucleotide encoding GPI-PLD or a biologically active fragment thereof, and cells transformed by such a vector.

In another embodiment, the present invention also relates to mutations of GPI-PLD or of biologically active fragments thereof which substantially retain the biological activity of natural GPI-PLD, polynucleotides coding for these mutants, vectors containing these polynucleotides, and cells transformed by such a vector.

The present invention also relates to a process for producing GPI-PLD, a biologically active fragment thereof or a mutant of GPI-PLD or a fragment thereof, comprising culturing a host containing a recombinant vector which codes for such a GPI-PLD active compound under appropriate conditions of growth so that said compound is expressed and isolating said compound.

Another embodiment of the present invention is a method for producing a secretable protein from a eukaryotic cell comprising co-transfecting a eukaryotic cell with a gene encoding a glycosyl phosphatidylinositol-anchored protein with glycosyl phosphatidylinositol-specific phospholipase D.

Additionally, the present invention relates to a process for cleaving proteins which are anchored to a cell by means of a glycosyl phosphatidyl inositol anchor comprising administering to the cell culture in which the cell is growing glycosyl phosphatidylinositol-specific phospholipase D in combination with a suitable detergent.

Finally, the present invention relates to antibodies specific to GPI-PLD substantially free from other proteins.

Brief Description of the Drawings

- Fig. 1. A Model of a GPI anchor structure. The COOH-terminal amino acid of the protein is linked to an ethanolamine residue which in turn is linked via a phosphodiester bond to a complex glycan moiety. The site of GPI-PLD hydrolysis is marked.
- Fig. 2. SDS-PAGE of Samples Purified from Hydroxyapatite and Zn-chelate Matrix Chromatographies. Samples (1-3 μ g) were run on 10% polyacrylamide gels under reducing conditions and were visualized by Coomassie Blue staining. Protein standards (prestained) were from Bethesda Research Labs. Lane 1: hydroxyapatite flow-through pool (\sim 3 μ g); lane 2: Zn-chelate pool 1 (\sim 1 μ g); lane 3: Zn-chelate pool 2 (\sim 3 μ g).
- Fig. 3. SDS-PAGE of Samples Purified by the Immunoaffinity Chromatography Procedure. Samples were run on 8.5% acrylamide gels under reducing conditions and were visualized by Coomassie Blue staining. Lane 1: immunoaffinity-eluate, \sim 10 μ g; lane 2: lectin Sepharose-eluate, \sim 5.0 μ g; lane 3: Mono Q-FPLC pool \sim 2.5 μ g.
- Fig. 4. Restriction Map and sequencing strategy of the spliced inserts from Clones pBJ1549 and pBJ1644. The bovine liver GPI-PLD cDNA inserts from the two lambda gt11 clones were subcloned into pGEM4Z (Promega Biotec, Madison, WI) and both strands sequenced using

Sequenase enzyme (U.S. Biochemical Corp., Cleveland, OH). Arrows with closed and open circles represent sequences determined from SP6/T7 promoter primers of smaller subclones and sequences determined from synthetic oligonucleotide primers, respectively. The positions of the translation start and stop codons are marked. Clones pBJ1549 and pBJ1644 extended from nucleotides 1-1577 and 1438-2578, respectively. A, Accl; b, BamHI; H, HindIII; K, KpnI; N, NcoI; P, PstI; S, SacI; V, PvuII.

Fig. 5. DNA sequence and deduced amino acid sequence of bovine liver GPI-PLD. The arrow marks the N-terminus of the mature protein. Regions showing sequence similarity to metal ion binding domains of integrin α subunits are underlined.

Fig. 6. Western Blot Analysis of Transfected COS Cell Media and Lysates. The complete 2.6 kb cloned cDNA was ligated into the HindIII/SmaI site of pBC12B1 and the recombinant plasmid, pBJ1682, introduced into COS-7 cells utilizing standard DEAE-dextran mediated methods. COS cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum for the first 24 hours then switched to serum-free DMEM containing 1% Nutridoma (Boehringer Mannheim, Indianapolis, IN) to rid of endogenous PLD. Media was collected 48 hours after switching to serum-free media, centrifuged to pellet any suspended cells and concentrated 15-fold using Centricon 10 (Amicon, Danvers, MA). Cell lysates were prepared at a concentration of 5×10^7 cell-equivalents per ml in 0.5% Nonidet P-40 in PBS containing aprotinin (30 μ g/ml), leupeptin (10 μ g/ml), pepstatin (10 μ g/ml), and phenylmethyl sulfonyl flouride (1 mM). Lysates were centrifuged at 13,000 g for 20 min at 4°C and the supernatant collected. After gel electrophoresis and blotting to nitrocellulose, proteins were detected using a pool of five monoclonal antibodies (1 μ g/ml each) against bovine serum GPI-PLD and alkalinephosphatase conjugated goat anti-mouse IgG (Jackson Immuno-Research, West Grove, PA). Lane 1, lysate of mock-transfected cells; Lane 2, medium from mock-transfected cells; Lane 3, equal amounts of lysate from pBJ1682-transfected cells and medium from mock-transfected cells; Lane 4, equal amounts of medium from pBJ1682-transfected cells and lysate from mock-transfected cells; Lane 5, 50 ng of purified serum GPI-PLD; Lane 6, 200 ng of purified serum GPI-PLD mixed with mock-transfected cell medium.

Fig. 7. Demonstration of GPI-PLD Activity in Transfected COS Cells by Hydrolysis of 3 H-labelled VSG. Mock-transfected or pBJ1682-transfected COS cells were switched to serum-free media 24 hours after transfection as described for Fig. 6. (A) Time dependence of phospholipase activity. At various time points after switching to serum-free medium, aliquots (10 μ l each) were withdrawn from the medium and assayed for phospholipase activity. One unit of activity was defined as the amount of enzyme hydrolyzing 1% of the [3 H]myristate-labelled VSG per min. Δ Δ indicates the activity in DNA-transfected cells; o.....o indicates the activity in mock-transfected cells. (B) Comparison of phospholipase activity in the medium and cell lysate. After cells were grown in serum-free medium for 44 hours, 10 μ l of medium was withdrawn and assayed for phospholipase activity. Cells lysates were prepared as described in Fig. 6 and assayed at the same time.

Fig. 8. Product Analysis of Hydrolyzed VSG by Thin-layer Chromatography. Samples (50 μ l) of pBJ1682- and mock-transfected COS cell media and GPI-PLD purified from serum were incubated at 37°C for 30 min with 100 μ l of VSG cocktail consisting of 40 μ M Tris-maleate, pH 7.0, 0.2% NP-40, and 3×10^4 cpm 3 H-labelled VSG. The reaction were terminated with the addition of 0.5 ml butanol and spiked with 25 μ g each of dimyristoyl phosphatidic acid (DMPA) and dimyristoyl glycerol (DMG). After phase separation by centrifugation, 0.35 ml of the upper butanol phases were evaporated to dryness and the reaction products resuspended in 20 μ l of CHCl_3 :MeOH (1:1, v/v) and spotted onto a silica gel 60F254 plate (Merck), along with DMPA and DMG standards. The plate was run in a solvent system consisting of CHCl_3 :pyridine:70% formic acid (50:30:7, v/v/v). After development for a distance of 10cm, the plate was air dried overnight and the standards visualized with iodine. Zones of 0.5 cm were scraped, eluted with 150 μ l CHCl_3 :MeOH:butanol (1:1:1, v/v/v), and counted in a scintillation fluor. O----O, mock-transfected cell media; \square ---- \square , pBJ1682-transfected cell media; *----*, purified serum GPI-PLD.

Fig. 9. Nucleotide sequence and deduced amino acid sequence of the human liver glycosyl phosphatidylinositol specific-phospholipase D.

Fig. 10. The Alignment of amino acid sequence of the human and bovine liver GPI-PLD mature protein.

Fig 11. Nucleotide sequence and deduced amino acid sequence of the human pancreatic glycosyl phosphatidylinositol specific-phospholipase D.

Fig. 12. SDS PAGE showing the expression of ELAM-1-GPI (Column A) and ELAM-1-2-GPI (Column B) with PLD and without PLD.

Additionally, in the present application the following abbreviations are used: GPI, glycosyl-phosphatidylinositol; PLD, phospholipase D; PI, phosphatidylinositol; VSG, variant surface glycoprotein; CHAPS, (3-[(3-cholamidopropyl) dimethyl- ammonio] 1-propanesulfonate; PEG, polyethylene glycol; BSA, bovine serum albumin; EGTA, ethylenebis(oxyethylenenitrilo) tetraacetic acid; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; HP(or FP)LC, high performance (or fast protein) liquid chromatography; PTH, phenylthiohydantoin; ELISA, enzyme-linked immunosorbent assay; HRP, horse radish peroxidase.

The teachings of all of the references cited herein are hereby incorporated by reference.

Detailed Description of the Invention

The present invention relates to glycosyl phosphatidylinositol-specific phospholipase D (GPI-PLD) or biologically active fragments thereof substantially free from other proteins. This enzyme selectively hydrolyzes the inositol-phosphate linkage of glycosyl phosphatidylinositol (GPI)-anchored proteins, GPI lipids and related molecules. See Figure 1.

The DNA sequence and deduced amino acid sequence of bovine liver GPI-PLD is shown in Figure 5; the DNA sequence and deduced amino acid sequence of human liver GPI-PLD is shown in Figure 9; and Figure 11 shows the DNA sequence and the deduced amino acid sequence of human pancreatic GPI-PLD. Using conventional methods of recombinant DNA technology, (see for example Maniatis et al., "Molecular Cloning - A Laboratory Manual". Cold Spring Harbor Laboratory, 1989) expression vectors encoding for recombinant GPI-PLD can be constructed. Upon introduction of these expression vectors into a prokaryotic and eukaryotic host, recombinant GPI-PLD is synthesized.

The invention also relates to a polynucleotide, either double or single stranded, coding for a GPI-PLD protein or a biologically active fragment thereof. The nucleotide sequences which are coding for bovine liver GPI-PLD, human liver GPI-PLD and human pancreatic GPI-PLD are shown in Figures 5, 9 and 11, respectively.

The invention therefore relates to these nucleotide sequences or to homologous or degenerate sequences thereof, that means to nucleotide sequences having the same function, but originating from a different species (e.g. from human) or to nucleotide sequences being degenerate in the genetic code. The polynucleotide can be obtained from natural sources or be prepared synthetically by methods known to the person skilled in the art.

Moreover, the invention relates to replicable microbial vectors containing a polynucleotide with a sequence which codes for a polypeptide having GPI-PLD activity, to host organisms transformed with such a replicable microbial vector, which host is capable of expressing the amino acid sequence encoded by said polynucleotide.

A wide variety of host/cloning vehicle combinations may be employed in cloning the double-stranded DNA. For example, useful cloning vehicles may consist of segments of chromosomal, nonchromosomal or synthetic DNA sequences, such as various known bacterial plasmids, e.g. plasmids from E. coli such as pBR322, phage DNA, and vectors derived from combinations of plasmids and phage DNAs such as plasmids which have been modified to employ phage DNA or other expression control sequences or yeast plasmids. Useful hosts include microorganisms, mammalian cells, plant cells and the like. Among them microorganisms and mammalian cells are preferably employed. As preferable microorganisms, there may be mentioned yeast and bacteria such as Escherichia coli or Actinomyces. Among mammalian hosts CHO cells are preferred.

A cloning vehicle or vector containing the foreign polynucleotide is employed to transform a host so as to permit that host to express the protein or portion thereof for which the polynucleotide codes. The selection of an appropriate host is also controlled by a number of factors recognized in the art. These include, for example, compatibility with the chosen vector, toxicity of proteins encoded by the hybrid plasmid, ease of recovery of the desired protein, expression characteristics, biosafety and costs. A suitable expression vector for use in the present invention is the eukaryotic expression plasmid pBC12BI (Cullen- (1987), Methods in Enzymology 152, 684-704). Other suitable cloning or expression vectors are disclosed in the examples or are known in the art.

The invention also relates to mutations of GPI-PLD or biologically active fragments thereof which substantially retain the biological activity of natural GPI-PLD. The invention also relates to a polynucleotide

coding for the mutant GPI-PLD or a biologically active fragment thereof. Furthermore, the invention relates to vectors containing the isolated polynucleotide coding for the mutant GPI-PLD or biologically active fragments thereof. These mutants can be produced by known methods such as site-specific mutagenesis of the DNA sequence and the mutant DNA construct inserted into an expression vector and the expression vector introduced into a suitable prokaryotic or eukaryotic host to produce a mutated form of GPI-PLD. A mutated form of GPI-PLD can also be produced by means of enzymatic cleavage of the GPI-PLD protein and solid phase synthesis. The mutated form of the protein can then be assayed for its ability to exhibit PLD activity by assays herein described.

According to the present invention, GPI-PLD is purified and characterized by the method described in Example 1. The procedure, which was developed and can be used for the purification of GPI-PLD, is discussed below and describes the identification of the active enzyme compounds obtained during the individual purification steps.

In this procedure, the bulk of serum albumin and some other contaminating proteins were removed by PEG precipitation. The supernatant was then chromatographed on Q Sepharose (anion exchange) followed by S-300 gel filtration chromatography. GPI-PLD activity eluted in the broad second protein peak with a molecular weight of ≥ 250 kDa. This broad elution of activity suggests that GPI-PLD in serum may form a complex with other serum proteins.

GPI-PLD was further purified by wheat germ lectin-Sepharose and hydroxyapatite chromatography. At this stage, GPI-PLD was about 10% pure as judged by SDS-PAGE using procedures described by Lemmli, U.K. (1970), Nature, 227, 680-685. The final stages of purification consisted of Zn-chelate chromatography, Mono Q-HPLC and Superose 12-HPLC. When hydroxyapatite-purified material was chromatographed on Zn-chelate, two GPI-PLD activity peaks were observed. The first activity peak (pool 1) eluted in the wash fractions, separated from the majority of contaminating proteins and had the higher specific activity. This pool contained a major protein band on SDS-PAGE with an apparent molecular weight of ~ 100 kDa in addition to other minor protein bands. The second activity peak (pool 2) eluted with 10 mM histidine and contained two major protein bands with molecular weights of ~ 100 and ~ 180 kDa and several minor components on SDS-PAGE.

The two pools of activity from Zn-chelate chromatography were separately further purified by Mono Q-HPLC. Zn-chelate pool 1 eluted as a single activity peak at 0.2 M NaCl on Mono Q-HPLC, corresponding to a single band of molecular weight ~ 100 kDa on SDS-PAGE as shown in Fig. 2, lane 2. In contrast, Zn-chelate pool 2 resolved into two peaks of activity at 0.2 M and 0.3 M NaCl on Mono Q-HPLC. Both peaks contained a major protein band of ~ 100 kDa and another band corresponding to ~ 180 kDa on SDS-PAGE as shown in Fig. 2 lane 3.

When material eluted in Zn-chelate pool 1 was analyzed by Superose 12-HPLC, the elution profile showed that the GPI-PLD eluted as a single peak with an apparent molecular weight of about 200 kDa as determined by molecular weight markers (Bio-Rad's Gel Filtration Standards), indicating that the enzyme exists as a dimer. However, when material in peak 2 of Zn-chelate pool 2 was analyzed by Superose 12-HPLC, three activity peaks were observed. Actual fractions were analyzed by SDS-PAGE and the results showed that the majority of GPI-PLD eluted in fractions corresponding to the region with molecular weights higher than 200 kDa suggesting that GPI-PLD eluted as higher molecular weight aggregates. The higher molecular weight aggregates (peak 1) exhibited higher specific activity toward VSG ($\sim 2.3 \times 10^4$ U/mg) than alkaline phosphatase (1.0×10^3 U/mg) as substrate.

Example 1 summarizes the purification of GPI-PLD from 2.5 liters of bovine serum utilizing the protocol described above, excluding the Superose 12-HPLC step. Dimer GPI-PLD purified from Zn-chelate, pool 1, showed the highest specific activity (6.3×10^5 and 4.5×10^5 U/mg against alkaline phosphatase and VSG, respectively). This represents a $\sim 2,250$ fold purification and an overall recovery of about 0.5% (Table 1).

The invention also relates to antibodies specific to GPI-PLD, fragments thereof or mutants thereof or mutants of GPI-PLD or fragments thereof substantially free from other proteins. These antibodies are suitable, e.g. for use in the purification of GPI-PLD active compounds as outlined below and in Example 1.

Production of Monoclonal Antibodies against GPI-PLD

Using a mixture of dimeric and aggregated GPI-PLD as immunogen, polyclonal antisera in mice against GPI-PLD were produced. All three immunized mice produced antibodies against the immunogen as determined by ELISA analysis. GPI-PLD activities were completely inactivated by antisera when purified or partially purified protein was used. When partially purified material was analyzed by immunoblotting, the 100-kDa protein was reactive with the antisera (data not shown).

To further confirm that the 100-kDa protein is GPI-PLD, monoclonal antibodies against the enzyme were

produced. Since serum contains GPI-PLD, hybridomas were grown in serum-free medium after fusion. We attempted to screen hybridomas by neutralization of GPI-PLD activity. Hybridoma supernatants were analyzed by ELISA. Clones secreting high levels of IgG antibodies were further screened in an immunodepletion assay against GPI-PLD activity. Twenty-four clones were obtained after subcloning. To further analyze the immunoprecipitated product, ^{125}I -labelled immunogen was used in an immunodepletion assay and the products analyzed by SDS-PAGE. The results show that the antibodies in the hybridoma supernatants selectively precipitated the GPI-PLD activity and the 100-kDa protein (data not shown).

The cells from ELISA-positive and immunodepletion-positive wells were subcloned. Twenty four clones were isolated and expanded as ascites tumors in BALB/cByJ mice. The monoclonal antibodies were purified and screened for their reactivity with the 100-kDa protein by immunoblotting analysis. Among them, nineteen showed strong reactivity. The immunoreactivity of the 100-kDa protein was dependent on antibody concentration and was saturated by excess antibody. Preabsorption of antibody with excess purified GPI-PLD diminished immunoreactivity. The purified antibodies were also screened for direct inhibition of GPI-PLD activity in solution. None of them inhibited GPI-PLD.

Purification of GPI-PLD by Immunoaffinity Chromatography

An experiment was carried out to determine which of the monoclonal antibodies would be most suitable for immunoaffinity chromatography. Antibodies with different affinities to GPI-PLD on ELISAs were separately coupled to CNBr-activated Sepharose. Crude bovine serum was loaded onto immunoaffinity columns and GPI-PLD activity was eluted by different reagents. The results showed that when weak affinity antibodies were used, bound GPI-PLD could be eluted with 3M MgCl_2 with about 60% recovery of activity. However, when high affinity antibodies were used, only a very small amount of GPI-PLD could be eluted with 3M MgCl_2 . Although SDS-PAGE analysis indicated that most of the remaining bound protein could be eluted with 0.1 M glycine-HCl buffer (pH 2.8), enzymatic activity was lost. A weak affinity antibody was therefore chosen for immunoaffinity purification. The eluate from immunoaffinity chromatography gave a specific activity of about 9.75×10^3 U/mg, representing a 123 fold purification (see Table 2). Based upon this specific activity (assuming that the purified enzyme has a specific activity of 4.5×10^5 U/mg) and SDS-PAGE analysis a GPI-PLD purity of about 2% was calculated. See Fig. 3 lane 1.

Since the immunoaffinity-purified GPI-PLD could not be stably stored in 3 M MgCl_2 , it was immediately diluted 6 fold with Buffer C (see Example 1) supplemented with 2.5 mM each CaCl_2 and zinc acetate. Calcium and zinc ions in the dilution buffer seemed to stabilize the enzyme activity, consistent with previous observations that the enzyme activity is dependent on calcium and zinc ions, but not Mg^{2+} . GPI-PLD in the diluted sample was then further purified on wheat germ lectin Sepharose. As shown in Table 2, a 10 fold purification was achieved with lectin Sepharose chromatography. On SDS-PAGE (Fig. 3, lane 2), the lectin Sepharose-eluate showed that although the major contaminating proteins were still in the sample, there was an enrichment of the 100-kDa GPI-PLD. GPI-PLD was further purified by Mono Q-FPLC. The elution profile showed that most of the activity eluted in a peak at 0.2 M NaCl, although a very small amount of activity also eluted at 0.3 M NaCl. When the samples were analyzed by SDS-PAGE, the major activity peak showed a single band with a molecular weight of 100 kDa. See Fig. 3 line 3. Samples in the minor activity peak also showed a very small amount (less than 10% of the total GPI-PLD recovered from the column) of 100-kDa protein together with other contaminating proteins. When the purified GPI-PLD was analyzed by Superose 12-HPLC, it eluted as a single peak with an apparent molecular weight of 200 kDa.

Table 2 in Example 1 summarizes the purification of GPI-PLD from 200 ml of bovine serum by the immunoaffinity chromatography protocol as described above. The specific activity of purified GPI-PLD from the immunoaffinity procedure was about the same as that obtained by the eight-step procedure. However, the overall recovery (26%) was much higher.

Characterization of GPI-PLD

The products of ^3H myristate labelled VSG hydrolysis by the purified GPI-PLD were analyzed by thin layer chromatography on silica gel using two different solvent systems (chloroform:pyridine:70% formic acid, 50:30:7 or chloroform:methanol:glacial acetic acid: H_2O , 50:30:8:4). The ^3H -labelled product co-migrated with a dimyristyl phosphatidic acid standard. Other potential phospholipase products such as myristic acid and 1,2-dimyristoyl glycerol were not detectable (i.e. less than 5 % of recovered radioactivity). This result was obtained with both the dimeric form and the higher molecular weight aggregates.

The sensitivity of the enzyme activities to EGTA and 1,10-phenanthroline was studied. Table 3 shows that all enzyme activities are inhibited by EGTA and 1,10-phenanthroline, indicating that all forms of GPI-

PLD share a metal ion requirement. To further study the physical properties of dimer and aggregates of GPI-PLD, purified GPI-PLD was labeled with ¹²⁵I and the different forms of GPI-PLD were separated by Superose 12-HPLC. Each form of GPI-PLD was then rerun on Superose 12-HPLC. The results showed that the elution positions of these forms remained unchanged, indicating that the forms are not in equilibrium with each other.

The 100-kDa proteins in dimer and larger aggregated forms were isolated by preparative SDS-PAGE and subjected to amino-terminal sequence analyses. The results show that all forms of GPI-PLD share the same amino terminal sequence (H₂N-X-G-I-S-T-(H)-I-E-I-G-X-(R)-A-L-E-F-L--). A search within the GenBank and NBRF data bases using the computer programs TFASTA and SEARCH showed no strong sequence homology to that of any other known protein.

The primary structural relationships between these forms of GPI-PLD were also studied by comparing their tryptic peptide maps. Both samples were digested with trypsin, and cleavage products were separated by reverse phase HPLC on a C₈ column. The tryptic peptide maps are almost identical, indicating that the two forms of GPI-PLD represent either the same protein or are structurally very similar.

The tryptic peptides were further analyzed by protein microsequence analysis. Table 4 in Example 1 summarizes sequences derived from nine peak fractions.

The invention also relates to a method for producing a secretable protein from a eukaryotic cell said process comprises

- a) transforming a host cell with a recombinant vector which codes for a polypeptide having GPI-PLD activity and with a recombinant vector coding for a GPI-anchored protein
- b) culturing the transformed cell under appropriate conditions of growth so that both proteins are expressed and
- c) isolating the protein from the culture medium the GPI-anchor of which is cleaved off.

Secretable proteins are produced by splicing the DNA sequence encoding the protein of interest together with a DNA sequence encoding for a peptide which signals the attachment of a glycosyl phosphatidylinositol-anchor (GPI-anchor) onto the protein. An example of such a C-terminal GPI signal peptide which signal for the attachment of a GPI-anchor onto a protein is a peptide with the C terminal 37 amino acids of CD16, namely:

Ser Thr Ile Ser Ser Phe Ser Pro Pro Gly Tyr Gln Val Ser Phe Cys Leu Val Met Val

21

37

Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr Asn Ile.

The DNA sequence encoding the C-terminal GPI signal peptide is spliced onto the DNA sequence encoding the functional domain of the proteins forming the protein-GPI-anchor construct. The protein-GPI-anchor hybrid construct is then co-transfected into a eukaryotic cell such as a COS cell with a gene encoding a GPI-PLD such that both the protein-GPI anchor signal peptide hybrid construct and the GPI-PLD gene are expressed. A GPI anchor is attached to the Protein forming a GPI-anchor-protein; GPI-PLD enzymes cleave the anchor and the protein is secreted from the cell. Examples of proteins which could be produced and secreted in this way are CD4, ELAM-1, cytokine receptors such as p70 of the IL-2 receptor, members of the integrin and selectin families to name just a few.

The invention also relates to a process for cleaving proteins which are anchored to a cell by means of a glycosyl phosphatidylinositol anchor comprising administering to a cell culture in which the cell is growing GPI-PLD in combination with a suitable detergent such as CHAPS or NONIDET P40. To cleave off a GPI-PLD anchor, the proteins need not necessarily be anchored to a cell.

The present invention is further illustrated by the following examples.

Example 1

Purification and Characterization of PLD

Materials -- Bovine serum was from Pel-Freez Biologicals. PEG-5000 was from Polyscience Inc. Hydroxyapatite Ultrogel was from IBF Biotechnics. CNBr-activated Sepharose, Q Sepharose, wheat germ lectin-Sepharose and Sephacryl S-300 were from Pharmacia. IODO-BEADS, and immobilized (Fractogel

TSK HW-65F) iminodiacetic acid was from Pierce. CHAPS, (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), phenyl methyl sulfonyl fluoride (PMSF), Triton X-114 and 100, Nonidet P40 and goat anti-mouse IgG agarose were from Sigma. HRP conjugated goat F(ab')₂ anti-mouse IgG was from TAGO. Female Balb/c and Balb/cByJ mice were from Charles River Labs and Jackson Labs, respectively.

These and other sources of reagents described in the specification are provided merely for convenience and are not meant to be limiting on the invention.

Solutions -- Buffer A: 10 mM HEPES, pH 7.0, 0.15 M NaCl, 0.1 mM MgCl₂ and 0.01 mM zinc acetate; Buffer B: 50 mM Tris, pH 7.5, 0.1 M NaCl, 0.5 mM PMSF and 0.02% NaN₃; Buffer C: 50 mM Tris, pH 7.5, 0.1 M NaCl, 0.6% CHAPS and 0.02% NaN₃.

GPI-PLD assays -- For the eight-step purification of GPI-PLD, the enzyme activity was assayed as described in Low, M. G., and Prasad, A. R. S. (1988) Proc. Natl. Acad. Sci. USA, 85, 980-984 using GPI-anchored placental alkaline phosphatase as substrate. Typically, the alkaline phosphatase substrate (0.05 ml containing 1 vol of alkaline phosphatase, purified as described in Malik, A.-S. and Low, M. G. (1986) Biochem. J., 240, 519-527, 2 vol of 1% NP-40 and 2 vol of 0.2 M Tris-maleate, pH 7) was incubated with aliquots of samples in a total volume of 0.2 ml for 30 min at 37° C. The mixture was then diluted with 0.8 ml of ice-cold Buffer A. An aliquot (0.05 ml) was removed and mixed with 0.2 ml of Buffer A and 0.25 ml of 2% precondensed Triton X-114. After sampling a 0.1 ml aliquot for assay of total alkaline phosphatase activity, the mixture was incubated at 37° C for 10 min, centrifuged immediately at room temperature for 2 min and a 0.1 ml aliquot of the upper (aqueous) phase sampled. Alkaline phosphatase activity was determined. Anchor degradation was measured by comparing the activity in the upper phase (i.e., the degraded form) with that in the total mixture before phase separation. One unit is arbitrarily defined as the amount of enzyme hydrolyzing 1% of the alkaline phosphatase per min under the assay conditions described.

For the purification of GPI-PLD by immunoaffinity chromatography VSG biosynthetically labelled with [³H]myristate was used as substrate. This was prepared by a modified procedure of a method described in Hereld, D., Krakow, J.L., Bangs, J. D., Hart, G. W., and Englund, P. T. (1986) J. Biol. Chem., 261, 13813-13819. Typically, T. brucei (Mltat 117 or 118) were prepared from infected rats, labelled with [³H]myristic acid in vitro and the ³H-labelled VSG was isolated. [³H]Myristate-labelled VSG (4,000-5,000 cpm, 2 µg) was mixed with 0.02 ml of 0.2 M Tris maleate, pH 7.0, 0.02 ml of 1% NP-40 and 0.06 ml of H₂O. The substrate (0.1 ml) was then incubated with the GPI-PLD sample (0.1 ml) for 30 min at 37° C. The reaction was stopped by the addition of 0.5 ml of butanol that had been saturated with 1 M ammonium hydroxide. After vortexing, the phases were separated by centrifugation at 1,500 x g for 3 min. The upper(butanol) phase (0.35 ml) was withdrawn, mixed with 4 ml of scintillation fluid, and counted. One unit of GPI-PLD activity using VSG as a substrate is arbitrarily defined as the amount of enzyme hydrolyzing 1% of the [³H]-myristate-labelled VSG per min.

To determine the substrate specificity of GPI-PLD, the products of [³H]myristate-labelled VSG hydrolysis by purified GPI-PLD were analyzed by thin-layer chromatography as described by Low, M. G., and Prasad, A. R. S. (1988) Proc. Natl. Acad. Sci. USA, 85, 980-984. Hydrolysis of [³H]choline-labelled phosphatidylcholine and [³H]inositol-labelled PI was determined by substituting them for VSG in the incubation mixture described above. Water soluble radioactivity released from the phospholipids was determined as described by Low, M. G., Stiernberg J., Waneck, G. L., Flavell, R. A., and Kincade, P. W. (1988) J. Immunol. Methods, 113, 101-111.

Purification of GPI-PLD by the Eight-step Procedure

The purification steps are summarized in Table 1.

Table 1. Purification of GPI-PLD by the Eight-step Procedure

Step	Protein (mg)	PLD Activity ^(a) (U)	Sp. Activity (U/A ₂₈₀)	Purification Factor
Bovine Serum	146,855	4.1×10^7	2.8×10^2	1
PEG Sup.	67,365	3.1×10^7	4.6×10^2	1.6
Fast Q	3,686	7.5×10^6	2.0×10^3	7.1
S-300	920	3.1×10^6	3.4×10^3	12.1
Wheat Germ Lectin	106	2.2×10^6	2.1×10^4	75
Hydroxyapatite	14	1.6×10^6	1.1×10^5	392
Zn-chelate, pool 1	0.8	4.1×10^5	5.1×10^5	1,821
pool 2	2.5	3.0×10^5	1.2×10^5	(b)
Mono Q (Zn-chelate Pool 1)				
peak 1	0.1	6.3×10^4	6.3×10^5	2,250
Mono Q (Zn-chelate Pool 2)				
peak 1	0.28	4.0×10^4	1.5×10^5	(b)
peak 2	0.4	1.5×10^4	3.8×10^4	(b)

(a) GPI-PLD activity was determined using alkaline phosphatase as substrate.

(b) Since portions of GPI-PLD in the sample were present as aggregates with low specific activities, the degree of purification could not be determined accurately.

Bovine serum (2.5 l) was thawed at 4°C in the presence of 0.5 mM PMSF and 0.02% NaN₃. With stirring at 4°C, PEG-5000 was gradually added to a final concentration of 9%. The mixture was stirred for an additional hour and centrifuged at 10,000 x g for 25 min. The supernatant was collected and diluted with an equal volume of Buffer B. All subsequent purification steps were performed at 4°C except where noted.

The diluted supernatant was loaded at a flow rate of 30 ml/min onto a Q Sepharose column (9 x 10 cm) equilibrated in Buffer B. After washing with the equilibration buffer, GPI-PLD activity was eluted with a linear gradient of 0.1-1.0 M NaCl in 4 l of 50 mM Tris, pH 7.5, 0.02% NaN₃ and 0.5 mM PMSF. Fractions containing activity were pooled and concentrated by YM-10 (Amicon) membrane filtration to approximately 200 ml. The concentrate was loaded at a flow rate of 3.8 ml/min onto two (10 x 53 cm) S-300 columns in Buffer B, linked in tandem. The activity fractions were pooled, and NaCl and CHAPS were added to final concentrations of 0.2 M and 0.6%, respectively, to minimize protein aggregation. Half of the sample was loaded (flow rate: 17 ml/hr) onto a 40 ml (2.5 cm diameter) wheat germ lectin column equilibrated in 50 mM Tris, pH 7.5, 0.2 M NaCl, 0.02% NaN₃ and 0.6% CHAPS. After washing, the GPI-PLD activity was eluted with equilibrium buffer containing 0.3 M N-acetylglucosamine. The eluates from two runs were combined and concentrated to 10 ml. Nine volumes of 5 mM NaPO₄, pH 6.8, 0.4% CHAPS and 0.02% NaN₃ were added and the sample was loaded at room temperature (flow rate: 3 ml/min) onto a 4.2 x 22 cm column of hydroxyapatite Ultrogel in 5 mM NaPO₄, pH 6.8, 0.6% CHAPS and 0.02% NaN₃. GPI-PLD activity was collected in the wash fractions, and the contaminating proteins were eluted with 0.5 M NaPO₄, pH 6.8, 0.6% CHAPS, and 0.02% NaN₃.

GPI-PLD active fractions from hydroxyapatite agarose chromatography were pooled, concentrated by

YM-10 membrane filtration to 21 ml, and the pH adjusted with the addition of a 20-fold dilution of 1 M Tris HCl, pH 7.5. The sample was loaded onto a column (1.5 x 5.0 cm) of iminodiacetic acid on Fractogel TSK HW-65F chelated with zinc and equilibrated in Buffer C. The first peak of activity was collected in 10-15 bed volumes of wash with equilibration buffer and a sharper second peak of activity was eluted with 10 mM histidine in equilibration buffer.

The two Zn-chelate pools of activity were concentrated individually by YM-10 membrane filtration. Each sample (5 ml) was injected onto a Mono Q (HR5/5, Pharmacia) column equilibrated in Buffer C (without NaN_3) at room temperature. GPI-PLD activities were eluted at a flow rate of 1 ml/min with a gradient of 0.1-0.19 M NaCl in 50 mM Tris, pH 7.5, and 0.6% CHAPS in 6 min, followed by isocratic elution at 0.19 M NaCl for 5 min and a gradient of 0.19-0.4 M NaCl in 14 min. Under these conditions, the first Zn-chelate pool eluted as one activity peak at 0.2 M NaCl whereas the second Zn-chelate pool resolved into two peaks of activity at 0.2 M and 0.3 M NaCl.

GPI-PLD active fractions from Mono Q-HPLC were pooled, concentrated, and each sample (0.4ml) injected onto a Superose 12-HPLC (HR 10/30, Pharmacia) column equilibrated in Buffer C. Proteins were eluted at a flow rate of 0.3 ml/min and 0.5 ml fractions were collected.

Purification of GPI-PLD by Immunoaffinity Chromatography

Monoclonal antibody PLD 216.1 was coupled to CNBr-activated Sepharose at a final concentration of 1 mg/ml resin. Bovine serum (200 ml) was centrifuged at 16,000 x g for 20 min, and the supernatant diluted with 1.2 liters of Buffer B plus 0.5% NP-40. After filtering through a 0.22 μm membrane (Nalgene filter unit), the sample was loaded onto an immunoaffinity column (20 ml, 2.5 x 4 cm) at a flow rate of 30 ml/hr. The column was then washed with 400 ml of Buffer C and GPI-PLD eluted with 3M MgCl_2 in Buffer C. Active fractions were pooled (100 ml, 40 mg) and immediately diluted with 6 volumes of Buffer C plus 2.5 mM each CaCl_2 and zinc acetate. The sample was then loaded at a flow rate of 30 ml/hr onto a 20 ml (2.5 cm diameter) wheat germ lectin Sepharose column in 50 mM Tris, pH 7.5, 0.2 M NaCl, 0.6% CHAPS, 0.02% NaN_3 plus 2.5 mM each CaCl_2 and zinc acetate (equilibrium buffer). After the column was washed, the sample was eluted with 0.3 M N-acetylglucosamine in equilibrium buffer.

The pool (60 ml, 2.5 mg) of wheat germ lectin Sepharose-eluate was concentrated by YM-10 membrane filtration to about 15 ml and diluted with an equal volume of 50 mM Tris, pH 7.5, and 0.6% CHAPS. The sample was then loaded onto Mono Q-FPLC equilibrated in Buffer C (without NaN_3) at room temperature. GPI-PLD was eluted at a flow rate of 1 ml/min with a gradient of NaCl as described above.

The results of the single purification steps are summarized in Table 2.

Table 2. Purification of GPI-PLD by Immunoaffinity Chromatography

Step	Protein (mg)	PLD Activity ^(a) (U)	Sp. Activity (U/A ₂₈₀)	Purification Factor
Bovine Serum	8,333	6.6×10^5	$7.9 \times 10^{(b)}$	1
Immunoaffinity	40	3.9×10^5	9.8×10^3	123
Wheat Germ Lectin	2.5	2.4×10^5	1.0×10^5	1,266
Mono Q-FPLC	0.4	1.7×10^5	4.3×10^5	5,443 ^(c)

(a) GPI-PLD activity was determined using [³H]-VSG as a substrate.

(b) The specific activity of GPI-PLD in bovine serum shown in this Table is somewhat lower than that in Table 1 due to the variability in the commercially available material.

(c) The purification factor shown in this table is higher than that in Table 1 due to the lower specific activity of the starting material.

From Table 2, it can be estimated that GPI-PLD exists in bovine serum at a concentration of approximately 7 μ g per ml.

Protein Determinations -- Protein concentration during purification was monitored by absorbance at 280 nm. In addition, the protein concentration of purified preparations was determined by the method of Bradford, M. (1976) Anal. Biochem., 72, 248-254 using Bio-Rad's protein assay reagent. One mg/ml of purified GPI-PLD corresponded to one optical density unit at 280 nm.

Tryptic Peptide Mapping -- The 100 kDa proteins in peaks 1 and 2 from Mono Q-HPLC were isolated by preparative SDS-PAGE. Proteins were recovered by electroelution in 67 mM N-ethylmorpholine acetate, pH 8.6, and 0.05% SDS as described in Hunkapillar, M. W., Lujan, E., Ostrader, F., and Hood, L. E. (1983) Methods Enzymol., 91, 227-236. After electroelution, proteins (100 μ g) were reduced with 10 mM dithiothreitol for 2 h at 37° C and alkylated with 20 mM iodoacetic acid for 30 min at room temperature in the dark. Additional 10 mM dithiothreitol was added to the mixture to stop the reaction. Samples were lyophilized and proteins precipitated with acetone:acetic acid: triethylamine:water (85:5:5:5, by vol.). The precipitated proteins were washed twice with ice-cold acetone, dried and resuspended in 0.3 ml 0.1 M NH₄HCO₃, pH 8.0, and 0.5 mM CaCl₂. Samples were digested for 16 hr at 37° C with TPCK-treated trypsin (Cooper Biomedical, 6 μ g total). The trypsin was added in three equal aliquots: the first at time zero, the second after 4 h, and the third after a 12 h incubation. Samples were acidified with formic acid to 15% and subjected to reverse phase HPLC on a C₈ column (Phase Separation Inc., 0.2 x 15 cm). Peptides were eluted (flow rate: 0.2 ml/min) with a gradient of acetonitrile (0-70%) in 0.1% trifluoroacetic acid.

Protein Sequencing-- Sequence analysis was performed using an Applied Biosystems (ABI, Foster City, CA) gas sequencer model 470A. PTH amino acids were identified "on line" with an ABI model 120A PTH analyzer using a reverse-phase C-18 column (2.1 x 220mm, ABI).

The sequences of the different tryptic peptides obtained this way are shown in Table 3.

Table 3. Sequences of Tryptic Peptides generated from GPI-PLD

Fragment (pmol)	Sequence
T ₅₆ (~50)	SPFLVEQFQEYFLGGLEDMAFXSTNI
T ₅₀ (~15)	SIXEMFIGSXQPLTHV
T ₄₄ (~75)	VYGYFPXIC(Q)SIFT
(~20)	MVADVNXHX(L)GPE
T ₃₈ (~80)	LGXAMTSADLNQDGYGDLVVGAPG(Y)X(H)PG
T ₃₇ (~150)	FGSAVAVLDFNVDGVPDLAVGAPSVGS(E)(K)
T ₃₅ (~120)	ALEFLHLQDGSIN YK
(~20)	HQDAYQAGSVFPDSF
T ₃₄ (~100)	HQDAYQAGSVFPDSFYPSICER
(~50)	VSFLTMLHLHQQGGSTR
T ₂₀ (~325)	AQYVLISPEAGSR
(~205)	FGSSV(I)TVR
T _{18a} (~110)	SNVTS (CPEEK)
	[FWYLP] R

Tryptic fragments of the SDS-PAGE-purified 100-kDa protein were subjected to amino-terminal microsequence analysis on a gas phase sequencer. "X" indicates positions in the sequence where PTH-amino acids were not identified. The numbers in parentheses indicate the estimated amount of peptide sequenced. The amino acids in parentheses indicate the most likely assignments.

- a The two peptides in this fraction exist in equimolar amounts and the first six residues in the assigned sequences may be exchanged with each other at the corresponding positions.

Preparation of Monoclonal Antibodies against GPI-PLD -- A female BALB/c mouse was immunized intraperitoneally with a mixture of two forms of mono Q-HPLC-purified GPI-PLD (60 µg protein) mixed 1:1 with Freund's complete adjuvant. Four weeks later, the mouse was boosted intraperitoneally with the same amount of immunogen in Freund's incomplete adjuvant. A test bleed was taken a week later and antiserum was checked by ELISA and by direct assay for neutralization of GPI-PLD activities.

Three days before fusion, the mouse was further boosted with 60 µg of immunogen by intravenous injection into the tail vein. Spleen cells from the mouse were fused with the myeloma cell line PAI-0 using procedures described by Thomas, P. E., Reik, L. M., Ryan, D. E., and Levin, W. (1984) J. Biol. Chem., 259, 3890-3899. Ten days after fusion, the cells were weaned into serum-free media (HL-1, Ventrex Laboratories) and 40 h later, supernatants were analyzed by ELISA for IgG production against the immunogen. ELISA positive cultures were expanded in serum-free media. Hybridoma exhibiting poor growth in serum-free media were grown in 0.5% horse serum. Under such conditions, endogenous horse serum GPI-PLD did not interfere with either the ELISA or immunodepletion assay. The established hybridoma cells were then grown as ascites tumors in pristane-primed BALB/cByJ mice. Anti-GPI-PLD monoclonal antibodies were purified from ascites fluids by caprylic acid and ammonium sulfate precipitation as described by Reik, L. M., Maines, S. L., Ryan, D. E., Levin, W., Bandiera, S., and Thomas, P. E. (1987) J. Immunol. Methods, 100,

123-130.

ELISA -- Non-competitive ELISA assays were run against mouse antiserum and culture supernatants as described by Thomas, P. E., Reik, L. M., Ryan, D. E., and Levin, W. (1984) J. Biol. Chem., 259, 3890-3899. Either immunogen or partially purified (wheat germ lectin- or Zn-chelate matrix-) GPI-PLD was coated onto 96-well polystyrene microtest plates. Binding of antibodies to GPI-PLD-coated plates was detected using HRP-conjugated second antibody and an appropriate chromogen as described by Thomas, P. E., Reik, L. M., Ryan, D. E., and Levin, W. (1984) J. Biol. Chem., 259, 3890-3899.

Immunodepletion assay -- Hybridoma supernatants were screened for their abilities to immunoprecipitate GPI-PLD activity. Culture supernatants (0.5 ml) were incubated with 50 μ l of a 50% suspension of goat anti-mouse IgG-agarose for 1 h at 37°C. BSA (0.5 mg) was added as a carrier protein. The beads were washed twice with 1 ml Buffer A plus 0.5% NP-40 and incubated with 40 μ l wheat germ lectin-purified GPI-PLD diluted with Buffer A plus 1 mg/ml BSA. After 1 h at 37°C, the beads were removed by centrifugation at 1,500 x g for 0.5 min, and the supernatants were analyzed for GPI-PLD activity using either alkaline phosphatase or ³H-VSG as substrate.

Immunoblotting -- Immunoblotting was carried out as previously described by Towbin, H., Staehlin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. USA, 76, 4350-4354. Antibodies (mouse antiserum or purified monoclonal antibodies) and second antibodies (HRP-goat F(ab')₂ anti-mouse IgG) were diluted in phosphate-buffered saline, 1% BSA, 5% normal goat serum, and 0.05% Tween 20. After several washes, peroxidase activity was detected with 4-chloro-1-naphthol and hydrogen peroxide, as previously described by Nielsen, P.J., Manchester, K. L., Towbin, H., Gordon, J., and Thomas, G. (1982) J. Biol. Chem., 257, 12316-12321.

Immunoprecipitation -- Dimer GPI-PLD was iodinated with ¹²⁵I using IODO-BEADS. Free ¹²⁵I was removed with a desalting column (Econo-Pac 10DG, Bio-Rad). Hybridoma supernatants (0.25 ml each) were incubated with goat anti-mouse IgG-agarose beads (0.05 ml of 50% slurry) at 37°C for 1.5 hr. BSA (0.2 mg) was added to each sample as a carrier protein during incubation. The mixtures were then centrifuged at 1,500 x g for 0.5 min, and the beads were incubated overnight at 4°C with ¹²⁵I-labelled GPI-PLD (3.5 x 10⁵ cpm) in 0.25 ml of 50 mM Tris, pH 7.5, 0.1 M NaCl, 0.5% NP-40, and 1 mg/ml BSA. The beads were removed by centrifugation and washed three times (0.8 ml each) with 50 mM Tris, pH 7.5, 0.1 M NaCl, and 0.5% NP-40. SDS-PAGE reducing sample buffer (40 μ l) was added to the beads and aliquots (20 μ l) were analyzed by SDS-PAGE. After electrophoresis, the gels were dried under vacuum and autoradiographed.

In summary, GPI-specific phospholipase D was purified from bovine serum by two different methods. The enzyme was initially purified by an eight-step procedure. Using the purified enzyme as immunogen, a panel of monoclonal antibodies against GPI-PLD were generated. Purified GPI-PLD from bovine serum was also accomplished by a simple procedure involving immunoaffinity chromatography, wheat germ lectin Sepharose and Mono Q-FPLC. The enzyme purified by the latter procedure is present as a dimer as analyzed by gel filtration-HPLC. However, the material purified by the eight-step procedure contains a mixture of dimer and higher molecular weight aggregates. These forms of GPI-PLD can be separated by Mono Q- and gel filtration-HPLC. On SDS-PAGE, the purified enzyme shows a single protein band with a molecular weight of 100 kDa. On native isoelectric focusing gels (data not shown), each form of GPI-PLD exhibits a common pI of about 5.6. Using VSG or alkaline phosphatase as substrate, the dimer exhibits a much higher specific activity than the higher aggregates.

When the 100-kDa protein and its tryptic peptides were subjected to amino acid sequencing analyses, the sequence data revealed no strong homologies to those of other known proteins except for the homology of two tryptic peptide sequences to each other and to the Ca²⁺ binding domains of calcium binding proteins. The discovery of two potential metal binding sequences is interesting in view of the data reported here that the enzyme activity is sensitive to the addition of divalent metal ion chelators, such as EGTA and 1,10-phenanthroline as shown in Table 4.

Table 4. Inhibitor Sensitivity of Two Forms of GPI-PLD

Enzyme (%)	Inhibitor	Activity remaining
GPI-PLD (dimer)		
	None	100
	EGTA (1.5 mM)	83
	EGTA (5.0 mM)	18
	1,10-phenanthroline (0.075 mM)	26
	1,10-phenanthroline (0.5 mM)	3
GPI-PLD (aggregates)		
	None	100
	EGTA (1.5 mM)	38
	EGTA (5.0 mM)	11
	1,10-phenanthroline (0.075 mM)	44
	1,10-phenanthroline (0.5 mM)	1.3

Mono Q-HPLC peaks 1 (A₂₈₀: 0.162) and 2 (A₂₈₀: 0.319) were diluted 400-fold with 10 mM HEPES, pH 7.0, and 0.15 M NaCl. An aliquot (0.1 ml) was incubated with various amounts of inhibitors for 1 hr at 4°C in a total volume of 0.11 ml. GPI-PLD activity was determined using VSG as substrate. Inhibitor concentrations refer to those present in the final incubation. Activities are expressed relative to those of controls.

Example 2

Cloning and Expression of Bovine Glycosyl Phosphatidyl Inositol-Specific Phospholipase D

Bovine liver cDNA libraries were screened with synthetic oligonucleotides corresponding to peptide sequences derived from purified bovine glycosyl phosphatidyl inositol-specific phospholipase D (GPI-PLD). Two overlapping clones were isolated that together predict the exact amino acid sequence of all eight tryptic fragments that had been sequenced. The DNA sequence of the two clones predicted a mature protein of 816 amino acids and an additional signal peptide of 23 amino acids. The deduced sequence contained eight potential N-linked glycosylation sites and at least four regions with sequence similarity to metal ion binding domains of members of the integrin family [Hynes, R.O. (1987) Cell, 48, 549-554]. These observations were consistent with the characterized GPI-PLD being 100 kd in size, glycosylated, and metal ion-dependent. The identification of the cloned cDNA was confirmed by two assays for biological activity. First, culture media and cell lysates of COS cells transfected with the gene showed phospholipase activity using ³H-labelled GPI-anchored variant surface glycoprotein (VSG) of the African trypanosome as substrate in an in vitro assay. Analysis of the products from the in vitro VSG assays by thin layer chromatography showed that phosphatidic acid was a reaction product confirming that the phospholipase activity was that of phospholipase D. Second, COS cells transfected with a gene encoding GPI-anchored placental alkaline phosphatase (PLAP) released significant amounts of PLAP into the media when co-transfected with the GPI-PLD clone but not when transfected alone. These results suggest that GPI-PLD may play a role in the regulation of cell surface expression of GPI-anchored proteins in vivo.

The amino acid sequence of eight tryptic fragments from bovine GPI-PLD was used to design a set of

four degenerate oligonucleotide probes for the purpose of screening by DNA hybridization bovine DNA libraries. Because PLD activity had been detected in liver extracts, a liver cDNA library was initially screened. No positive clones were detected among the 5×10^5 clones screened. However, the screening of a bovine genomic library yielded one positive clone that hybridized to one of the four oligonucleotide probes. Partial DNA sequence analysis of this clone revealed an open reading frame that predicted exactly the sequence of the 22 amino acid tryptic fragment, T34. However, this coding sequence was in an exon that appeared to be only 79 bp in length. Instead of characterizing this genomic clone further, a second attempt at isolating a cDNA clone was made using two non-degenerate 30-mer oligonucleotides corresponding to the 79 bp exon sequence. In addition, a new bovine liver cDNA library was constructed using random hexanucleotides to prime first strand synthesis. From 5×10^5 clones screened, two positive ones were isolated with the longer insert being 1.6 kb in length (clone pBJ1549). The complete sequence of the 1.6 kb insert was determined and shown to predict exactly the amino acid sequence of five of the eight tryptic fragments reported including (as expected) fragment T34 encoded by the genomic clone. Comparison of the deduced protein sequence to the N-terminal sequence of intact GPI-PLD revealed that the clone encoded the mature N-terminus of the protein (Cys¹ in Fig. 5). That means, that the initial translation product contains a 23 amino acid peptide.

Clone pBJ1549 was considered incomplete because 1) it encoded a protein of only 50 kd while a core protein of 80-100 kd was expected, 2) three of the eight tryptic sequences were not accounted for, and 3) an in-frame translation stop codon was not present. To isolate clones encoding the C-terminus, a liver cDNA library was screened with a nick-translated 400 bp fragment from the 3' end of pBJ1549. One clone was isolated that had a 1.1 kb insert (clone pBJ1644). Sequence analysis showed that the insert began at nucleotide 1450 of pBJ1549 and extended 1090 nucleotides in the direction of the C-terminus. The two clones had identical sequences in the 140 base region of overlap. The open reading frame identified in pBJ1549 continued in pBJ1644 until a stop codon at nucleotide 2557. The pBJ1644 insert encoded exactly the three tryptic fragments not encoded by pBJ1549. Together they encoded a 23 amino acid signal peptide and a 816 amino acid mature protein (90.2 kd) with eight possible N-linked glycosylation sites. These data indicated that these two clones combined contained the complete coding sequence for this protein.

Analysis of the deduced amino acid sequence revealed four regions of internal similarity (amino acids 379-402, 448-471, 511-534, and 716-739) that ranged from 21% to 54% identical (54% to 75% similar) to each other. A computer search in amino acid and nucleotide sequence databases revealed significant similarity of these repeats with the metal ion binding domains of the integrin alpha subunits. They share an aspartate-rich core sequence flanked by short conserved segments which are unique to the integrins. Apart from the absence of a glutamate residue, the core sequence DX(D/N)XDGXXD matches the EF-hand consensus motif characteristic of a number of Ca²⁺ and Mg²⁺ binding proteins such as calmodulin, troponin C, and parvalbumin. The observation that the gene reported here contains domains similar to metal ion binding domains of the integrins is consistent with the calcium requirements of GPI-PLD in enzymatic assays.

To express the cloned cDNAs and confirm that the encoded protein was GPI-PLD, the two inserts were first spliced together at the *AccI* site in their region of overlap and the resulting 2.6 kb cDNA ligated into the eukaryotic expression plasmid, pBC12BI (Cullen (1987) *Methods in Enzymology* 152, 684-704). The resulting plasmid, pBJ1682, was introduced into COS cells and expression confirmed by using a pool of monoclonal antibodies against the purified serum enzyme to perform 1) immunofluorescence of permeabilized cells (data not shown), and 2) Western blot analysis. While mock-transfected cell medium and lysate showed no detectable immunoreactive proteins by Western blot (lanes 1 and 2 in Figure 6), pBJ1682-transfected cells produced an immunoreactive protein detectable in both the medium and the lysate of sizes consistent with that of a glycosylated 90 kd core protein (lanes 3 and 4). However, the protein detected in the lysate migrated slightly faster than the protein secreted into the medium which in turn migrated faster than purified serum GPI-PLD. To demonstrate that these differences in migration were not due to differences in the types of sample (e.g. lysate vs. medium), pBJ1682-transfected cell medium or lysates were mixed with an equal volume of mock-transfected cell lysate or medium, respectively, prior to loading on the gel. The nature of these differences in size (estimated to be as much as 10 kd between lysate and purified serum proteins) may provide an important clue as to how the active form of this enzyme differs from its inactive form.

Culture media and cell lysates of the pBJ1682-transfected or mock-transfected COS cells were then prepared and incubated with ³H-labelled GPI-anchored variant surface glycoprotein (VSG) to test for phospholipase activity. As shown in Fig. 7A, significant amount of phospholipase activity was detected in the medium of DNA-transfected cells while only background levels of activity was detected in mock-

transfected cells. After 46 hours in serum-free medium, the amount of phospholipase activity secreted reached 65 U/ml (approximately 0.15 µg/ml assuming that the COS cell secreted enzyme had the same specific activity as the purified bovine serum enzyme). Fig. 7B shows that from pBJ1682-transfected cells only a small amount of phospholipase activity was observed in the lysates compared to the media. These results indicated that the cloned gene did encode phospholipase enzyme and that most of the enzymatic activity was secreted from the cells.

Analysis of the reaction products of ³H-labelled VSG hydrolysis assays confirmed that the phospholipase activity in DNA-transfected cells was that of phospholipase D (see Figure 8). The major ³H-labelled product resulting from hydrolysis by purified serum GPI-PLD or the conditioned media from transfected cells co-migrated with dimyristoyl phosphatidic acid during thin-layer chromatography.

Transfected COS cell lysates and conditioned media were also examined for their specificities against non-GPI linked dipalmitoyl phosphatidylcholine substrate in the presence of ethanol. Neither PA nor phosphatidylethanol (a transphosphatidyl transfer product of Phosphatidylcholine-specific PLD in the presence of ethanol) were detected by thin layer chromatography (data not shown) confirming that the cloned gene was the GPI-specific form of PLD.

Example 3

Transfection of COS Cell with a Gene encoding GPI-Anchored Protein alone and with a Gene encoding for GPI-PLD

To test for in vivo phospholipase activity against a GPI-anchored substrate, COS cells were transfected with a gene encoding GPI-anchored placental alkaline phosphatase (PLAP) alone or co-transfected with pBJ1682. Cell media and lysates were assayed for alkaline phosphatase activity. When COS cells were transfected with the PLAP cDNA alone, the majority of PLAP activity was detected in the cell lysate. This was consistent with PLAP being a GPI-anchored protein. When COS cells were co-transfected with both PLAP and pBJ1682, the amount of PLAP secreted into the medium was much higher than that of cells transfected with PLAP cDNA alone. The PLAP activity in the lysate of co-transfected cells was slightly higher than that of cells transfected with PLAP only, suggesting that in cotransfected cells GPI-anchored PLAP was constantly being synthesized and released by phospholipase activity. This was also supported by the fact that the total PLAP activity detected in the medium and lysates of co-transfected cells was consistently much higher than that in cells transfected with PLAP alone. In COS cells transfected with pBJ1682 DNA alone, only background levels of endogenous PLAP were detected in the medium or lysates. These results demonstrated that the cloned phospholipase could greatly affect the cell-surface expression of a GPI-anchored protein.

To test whether the GPI-PLD secreted from COS cells would hydrolyze cell-surface GPI-anchored PLAP, media from pBJ1682-transfected cells was incubated with PLAP-transfected cells and aliquots of media were assayed for PLAP activity after 1, 3, 8 and 24 hours of incubation. No PLAP activity was detected even though the media was active in the VSG assay both before and after the 24 hour incubation period.

As an alternative means of determining whether GPI-anchored proteins were hydrolysed by GPI-PLD, the cell culture supernatants of cotransfected COS cells were examined by immunoprecipitation following labelling with ³H-ethanolamine. If GPI-anchored proteins were actually being hydrolyzed by GPI-PLD, then the hydrolyzed products would be expected to maintain the ³H-ethanolamine moiety hydrolytic products derived by proteolysis, which would not contain this group. Both PLAP and CD16 can be released from GPI-PLD co-transfected cells in a form which still contains an ethanolamine residue. These results eliminate the possibility that the released proteins are proteolytically derived products, and demonstrate that at least two different GPI-anchored proteins can be released by GPI-PLD.

Example 4

Molecular Cloning of the Human Liver Phospholipase D Gene

Tryptic peptide fragment sequences of a bovine GPI-PLD and DNA sequence from a partial bovine genomic clone were available. Using this information, a pair of oligonucleotides (#1s, #1a) were designed to search for a human source of PLD mRNA by the polymerase chain reaction. In liver, the presence of the message was detected by a 81-bp amplicon. Based on bovine cDNA sequences, primers were prepared (#5s, #4a) to amplify the 1.2kb fragment corresponding to the 5' half of the phospholipase D transcript from

human liver first-strand cDNA.

A partial human GPI-PLD cDNA clone was isolated by library screening. Human liver polyA⁺ mRNA was primed using oligo-dT and size selected. EcoRI-linked cDNA was cloned into the lambda-ZAP II vector (Stratagene). This library of 2.5 million recombinants was screened unamplified in duplicate with the bovine cDNA (at low stringency) and the 1.2-kb human GPI-PLD amplicon (at high stringency). A positive clone was identified by both probes and the insert was sequenced. This partial cDNA clone (nucleotide 688-1247) encoded 186 amino acid residues (230-416).

Since the mature amino terminus of human GPI-PLD was found to be highly conserved with that of the bovine protein (11 amino acids identical of the first 12) and partial C-terminus sequence of a human pancreas PLD cDNA was available, two oligonucleotides (#5s, #9a) were made to amplify a 2.5-kb amplicon from human liver first-strand cDNA. The segment corresponds to sequence coding for the mature human phospholipase D gene product. The amplicon was cloned into the vector pRcCMV (Invitrogen) and pBC12BI-derived vectors for expression in mammalian cells.

The DNA sequence coding for the mature human GPI-PLD protein was obtained from two independently isolated clones of the 2.5 kb amplicon, the partial cDNA clone and the 1.2 kb amplicon (described above; see Fig. 9). The predicted peptide sequence is 817 amino acid and 82% identical to the bovine sequence.

To clone the signal peptide of human GPI-PLD, an oligonucleotide (#5RT) was designed to prime cDNA synthesis from liver polyA⁺ RNA. An adaptor-linker was ligated to the ends of the cDNA which was then subjected to two rounds of PCR using an adaptor primer and the oligonucleotides #5amp followed by #237. A 300 bp amplicon detected by #5s on a Southern blot was subcloned and the sequence of seven clones were determined. The signal peptide of human liver GPI-PLD is 24 amino acids long and the sequence matched closely to that of the bovine GPI-PLD (14 amino acids identical). The human liver signal peptide was joined to the mature protein coding region via a HpaI site in the pRcCMV expression construct.

The following oligonucleotides and PCR-conditions were used in the procedure described above.

Oligonucleotides

#	Sequence	nucleotide positions
1s:	CTGTTACTTAGGCACCAGG	bovine 85-103
1a:	CTCTCTCACAGATGCTAGG	bovine 144-162
5s:	TGTGGCCTTTTCGACACACATAGAAATAGG	human 1-29
4a:	ACGCGCCCCACGTGAATGCGGCCTGGGTG	bovine 1150-1178
9a:	TCAATCTGAGCCAAGGCTATAGAC	human 2430-2453
5RT:	GAATCCTTGTTCAATG	human liver 411-426
5amp	CTGCTACCATATGAGAAGTA	human liver 388-369
237:	TATGCATCCTGGTCTTCT	human liver 182-165

Plasmid or genomic DNA, single stranded cDNA, or lambda phage have been used as template in PCR. A 50µl-reaction contains 10mM Tris-HCl pH8.3 at 25°C, 1.5 mM MgCl₂, 50mM KCl, 0.01%(w/v) gelatin, template DNA, a pair of oligonucleotide primers (50pmol each), 2.5 units Taq DNA polymerase (Cetus-Perkin Elmer) and 200µM of dATP, dCTP, dGTP, dTTP. Template DNA was denatured at 94°C for 7 minutes. The amplification was carried out in a Perkin-Elmer thermocycler for 25-35 cycles. Each cycle consists of a denaturation step set at 94°C for 1 min, an annealing step at 55°C for 2 min and an extension step at 72°C for 3 min. The denaturation step of the first cycle was extended to 7 min and an extra 72°C, 10 min extension step was included at the end of the cycles. The PCR products were analyzed in an 1-4% agarose gel. Amplified DNA was excised from gel, purified on glass beads (GeneClean) and subcloned into the HincII site of the general purpose cloning vector pBS (Stratagene).

The Library Construction & Screening was performed as follows:

Human liver mRNA was purchased from Clontech Labs and cDNA was synthesized by the procedure of Gubler and Hoffmann (1983). In a 50 μ l reaction (50mM Tris-HCl pH8.3, 75mM KCl, 3mM MgCl₂, 10mM DTT, 0.5mM dATP, 0.5mM dCTP, 0.5mM dGTP, 0.5mM dTTP), 1 μ g of mRNA primed with 1.25 μ g oligo-dT was converted into single stranded cDNA using the RNaseH negative MMLV-reverse transcriptase (BRL). The reaction was incubated at 37°C for 1 hour. The yield was monitored by adding 10 μ Ci ³²P-dCTP to the reaction and measuring incorporated radioactivity after TCA precipitation.

Second strand synthesis was carried out as follows using buffers from the Amersham cDNA synthesis and cloning kit. The 250 μ l-reaction contains 50 μ l of 1st strand synthesis reaction, 93.5 μ l 2nd strand synthesis buffer, 4U RNaseH, 115U DNA polymerase I and 91.5 μ l water. The synthesis was carried out at 14°C for 1 hr, then at room temperature for 1 hr followed by an 10-min incubation at 70°C. 2 μ l T4 DNA polymerase (4 U/ μ l) was added and the mix incubated for 10 min at 37°C. The yield of the reaction was estimated by counting TCA precipitated cDNA. Purified double-stranded cDNA was methylated in a 20- μ l reaction containing 4 μ l of M buffer, 1x s-adenosylmethionine and 30U of EcoRI methylase. The mixture was incubated at 37°C for 1 hr and then 10 min at 70°C to inactivate the enzyme. EcoRI linkers (1.5 μ g) were ligated to methylated cDNA (1.5 μ g) in an overnight reaction at 15°C in 50mM Tris-HCl pH7.5, 10mM MgCl₂, 10mM DTT, 1mM ATP and T4 DNA ligase. The linked cDNA was digested with EcoRI (100U) in a 100 μ l reaction for 5 hrs at 37°C. Digested cDNA was then size fractionated in a Sephacryl S500 column and high molecular weight fractions were pooled and purified.

The gene library was constructed in the vector, lambda ZAPII (Stratagen). cDNA was ligated to the EcoRI-digested phosphorylated vector overnight at 14°C in a 10 μ l reaction containing T4 DNA ligase and its buffer. Ligated cDNA was packaged into phage using the Gigapack kit under conditions suggested by Stratagene.

A library of 2.5 million clones was generated and plated out on XL-1 blue cells and duplicate set of filters were lifted. The procedure for plaque hybridization of Benton & Davis (1977) Science 196, 180-182, was followed. A radioactive ³²P labelled DNA probe (2.5x10⁸cpm/ μ g) was prepared by the random priming method (Feinberg & Vogelstein (1984) Anal. Biochem. 137, 266-267). Hybridization was carried out in 6xSSC, 0.1% SDS, 5x Denhardt's, 100 μ g/ml salmon sperm DNA, 25-50% formamide at 42°C overnight. The filters were washed in 0.1-2x SSC, 0.1% SDS at 37°C (low stringency) or 55°C (high stringency) before autoradiography.

DNA Sequencing

Double stranded plasmid DNA was sequenced according to the procedure described in the Sequenase (USB) manual. Figure 9 shows the nucleotide sequence and translated amino acid sequence of the human liver GPI-PLD. Figure 10 shows the alignment of amino acid sequence of the human and bovine liver GPI-PLD mature protein.

Example 5

Isolation and Characterization of a Human Pancreatic Phospholipase D cDNA Clone

Total RNA was isolated from a human pancreas tumor as described by Gubler et al., (1983) Proc. Natl. Acad. Sci. U.S.A. 80, 4311-4314. Poly A⁺ RNA was selected resulting in a yield of 2.5%(w/w) relative to the total amount of RNA input. A cDNA library was constructed in λ gt11 and amplified according to procedures published in Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press 1989. The cDNA library was screened using the bovine GPI-PLD nick-translated cDNA as a probe [see Kocha, J. et al. (1986) Cell 44, 689-696] under conditions of reduced stringency (25% formamide). Two positive clones were plaque purified, cDNA inserts were subcloned in pGem3z (Promega Biotec) and their sequence determined using the dideoxy sequencing technique as recommended by the manufacturer of sequenase (United States Biochemical Corp.) The sequence of clone pJJ1935a is shown in Fig. 11 and begins at nucleotide 1 (corresponding to nucleotide 1609 of the bovine GP-PLD nucleotide). The sequence of clone pJJ1939 begins at nucleotide position 410 of pJJ1935a and is identical to pJJ1935a.

Analysis of the partial amino acid sequence of the human pancreas GPI-PLD reveals a high level of identity (81%) when compared to the bovine amino acid sequence, and 84% identity at the nucleotide level.

Example 6

Novel Process for the Production of recombinant, secretable Proteins

Other proteins that are normally not GPI-anchored can be made to be GPI-anchored by modifying their gens to encode the signal sequence for GPI-attachment at their 3' ends. If cells are transfected with both this modified gene and the gen for GPI-PLD, the protein gets secreted.

To determine if the principle of GPI-anchor protein secretion could be applied in general to other proteins, the GPI-anchor of CD16 was tranfered to other proteins, and their expression was monitored in the presence or absence of GPI-PLD. A DNA fragment encoding the portion of CD16 that signals GPI attachment [See Scallon et al., Proc. Natl. Acad. Sci. USA 86,5079-5083 (1989), Selvaraj et al., Nature 333, 565-567 (1988) and Simmons et al., Nature 333,568-570 (1988)], namely the C-terminal 37 amino acids.

Ser Thr Ile Ser Ser Phe Ser Pro Pro Gly Tyr Gln Val Ser Phe Cys Leu Val Met Val
21 37
Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr Asn Ile,

was spliced to DNA encoding the extracellular domains of hte Endothelial Leukocyte Adhesion Molecule-1 (ELAM-1) [See Bevilacqua, M.P. et al., (1989) Science 243, 1160-1165]; and to DNA encoding the extracellular domains of the p70 subunit of the IL-2 receptor (Hatakeyama, M. et al., (1989) Science 244, 551-556) by general methods common to the art.

Specifically for the ELAM-1, two independent constructs were made using PCR technology, namely, ELAM-1-1-GPI and ELAM-1-2-GPI. For ELAM-1-1-GPI the oligonucleotide 5'-TTTGATCATTCTCTCAGCTCTCACTTTG-3' (5' sense primer) and 5'-TGGTCGACTCAGTGGGAGCTTCACAGGT-3' (3' anti-sense primer) were used to generate an amplicon. This amplicon was then digested with the restricton enzymes Bell and Sall and contained the ELAM
extracellular coding sequences (amino acids 15-532) used for the ELAM-1-GPI construct. For ELAM-1-2-GPI, the oligonucleotides 5'-TTTGATCATTCTCTCAGCTCTCACTTTG-3' (5' sense primer) and 5'-TAGTCGACACAATTTGCTCACACTTGAG-3' (3' anti-sense primer) were used to generate an amplicon. This amplicon was then digested with the restriction enzymes Bell and Sall and contained the ELAM-1
extracellular coding sequences (amino acids 15-157) used for the ELAM-1-2-GPI construct.

For p70-GPI the oligonucleotides 5'-ACGTCGACGTGTCCTTCCCAAGGGCTGC-3 (3' anti-sense primer) and 5'-CCGGATCCTGTCTGCGTCTGCCCTC3' (5' sense primer) were used to generate an amplicon. This amplicon was digested with the restriction enzymes BamHI and Sall and contained the p70 extracel-
lular coding sequences (amino acids 21-214) used for the p70-GPI construct.

The C-terminal GPI signal peptide from CD16 was also isolated by using PCR technology. The
oligonucleotides 5'-GTGTGACCATCTCATCTCTCCA-3' (5' sense primer) and 5'-AGTGTGTTGTAGCTCTGAACTT-3' (3' anti-sense primer) were used to generate an amplicon, which was digested with the restriction enzymes Sall and Stul (internal site in the amplicon) and encoded amino acids 180-2167 of the CD16 protein. To generate the various GPI chimeric constructs, the protein coding regions of the protein of interest were ligated to the CD16 GPI-anchor sequences and in turn ligated into the
eukaryotic expression vector pBC12BI (which had been digested with BamHI and SmaI). The different GPI-
constructs were identified by colony hybridization, and verified by restriction enzyme analysis and DNA sequencing.

To determine if the hybrid GPI-proteins were secreted when cotransfected with the GPI-PLD, COS cells were transfected with ELAM-1-1-GPI (Fig. 12A), ELAM-1-2-GPI (Fig. 12 B) or p70-GPI (not shown) in the presence or absence of pBJ1682. Two days after transfection, the cells were metabolically labelled with ³⁵S-cysteine for two hours. The cell media or extracts were immunoprecipitated using antibodies directed against the protein of interest, fractionated by SDS-PAGE and visualized by fluorography. The protein of interest was detected in all of the cell extracts examined but was only found in the supernatant when the GPI-PLD construct was co-transfected. These results demonstrate that a GPI-anchor can be attached to a protein which his not normally GPI-anchored, and that this novel hybrid protein is secreted if it is expressed in the presence of the GPI-PLD enzyme. Such a secreted protein may be therapeutically relevant in the traeatment of various disesease depending on the hybrid protein which is used.

The teachings of all of the references cited in the present application including those listed below are

incorporated herein by reference.

REFERENCES

1. Low, M. G., and Saltiel, A.R. (1988) *Science*, 239, 268-275.
2. Low, M. G. (1987) *Biochem. J.*, 244, 1-13
3. Ferguson, M. A. J., and Williams, A. F. (1988) *Annu. Rev. Biochem.*,
4. Low, M. G. (1989) *Biochem. Biophys. Acta*, 988, 427-454
5. Ponez, M., Eisman, R., Heidenreich, R., Silver, S. M., Vilaire, G., Surrey, E., Schwartz, E., and
 Bennet, J. S. (1987) *J. Biol. Chem.*, 262, 8476-8482
6. Argraves, W. S., Suzuki, S., Arai, H., Thompson, K., Pierschbacher, M. D. and Ruoslahti, E. (1987)
J. Cell Biol., 105, 1183-1190
7. Suzuki, S., Argraves, W. S., Arai, H., Languino, L. R., Pierschbacher, M. D., and Ruoslahti, E.
 (1987) *J. Biol. Chem.*, 262, 14080-14085
8. Kretsinger, R. H. (1976) *Annu. Rev. Biochem.*, 45, 239-266
9. Herzberg, O., and James, M. N. G. (1985) *Biochemistry*, 24, 5298-5302
10. Davitz, M. A., Hom, J., and Schenkman, S. (1989) *J. Biol. Chem.* 264, 13760-13764
11. Saiki, R.K., Gelford, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis K.B., and Erlich,
 H.A., *Science* 239, 487-491 (1988)
12. Gubler, U., and Hoffmann B.J., *Gene* 25, 263-269 (1983)

Claims

1. The protein glycosyl phosphatidylinositol-specific phospholipase D (GPI-PLD) or biological active frag-
 ments thereof, substantially free from other proteins.
2. A glycosyl phosphatidylinositol-specific phospholipase D active compound which is a mutant of a
 compound as claimed in claim 1.
3. A compound as claimed in claims 1 or 2, wherein the protein of claim 1 is bovine liver GPI-PLD.
4. A compound as claimed in claim 3, wherein the bovine liver GPI-PLD has the amino acid sequence as
 set forth in Figure 5.
5. A compound as claimed in claim 1 or 2, wherein the protein of claim 1 is human liver GPI-PLD.
6. A compound as claimed in claim 5, wherein the human liver GPI-PLD has the amino acid sequence as
 set forth in Figure 9.
7. A compound as claimed in claim 1 or 2, wherein the protein of claim 1 is human pancreatic GPI-PLD.
8. A compound as claimed in claim 7, wherein the human pancreatic GPI-PLD has the partial amino acid
 sequence as set forth in Figure 11.
9. A glycosyl phosphatidylinositol-specific phospholipase D active fragment of a compound as claimed in
 anyone of claims 3-8.
10. A glycosyl phosphatidylinositol-specific phospholipase D active mutant of a compound as claimed in
 anyone of claims 3-8.
11. A glycosyl phosphatidylinositol-specific phospholipase D active fragment of a mutant of a compound as
 claimed in anyone of claims 3-8.
12. A polynucleotide coding for a protein as claimed in anyone of claims 1-11 or the complementary strand
 thereto.
13. A recombinant vector containing a polynucleotide as claimed in claim 12 operatively linked to an
 expression DNA-sequence.

14. A recombinant vector of claim 13 which is a plasmid or viral vector capable of replication in a eukaryotic or prokaryotic cell.
- 5 15. A prokaryotic or eukaryotic host cell transformed or transfected with a vector as claimed in anyone of claims 13 or 14.
16. A process for producing a protein as claimed in anyone of claims 1-11, comprising culturing a host containing a recombinant vector as claimed in anyone of claims 13 or 14 under appropriate conditions of growth so that said protein is expressed and isolating said protein.
- 10 17. A process of claim 16, wherein the host are CHO cells.
18. A process for secreting a protein from a cell which process comprises
- 15 a) transforming a host cell with a recombinant vector as claimed in anyone of claim 13 or 14 and with a recombinant vector coding for a GPI-anchored protein
- b) culturing the transformed cell under appropriate conditions of growth so that both proteins are expressed and
- c) isolating the protein from the culture medium the GPI-anchor of which is cleaved off.
- 20 19. A process claim 18, wherein the GPI-anchored protein is formed by splicing a C-terminal GPI-signal peptide to a protein of interest
20. A process of claim 19, wherein the C-terminal GPI-signal peptide is derived from the CD16 protein.
- 25 21. The use of a protein as claimed in anyone of claims 1-11 for cleaving of proteins which are attached to a glycosyl phosphatidylinositol anchor, characterized in that a protein attached to a GPI-anchor is cleaved from the GPI-anchor by reaction with said protein and a suitable detergent.
22. Antibodies specific to a protein as claimed in anyone of claims 1-11.

30

35

40

45

50

55

FIG 1




FIG 2




FIG 3




FIG 4




FIG 5

GCATTGCTCGTCACCATAGGAGCGGGGAGTAATGAGAGC	Met Ser Ala Phe Arg Phe Trp Ser Gly Leu	-14
ATG TCT GCT TTC AGA TTC TGG TCA GGA CTG		69
Leu Met Leu Leu Gly Phe Leu Cys Pro Arg Ser Ser Pro Cys Gly Ile Ser Thr His Ile		7
CTG ATG CTA CTG GGC TTC CTC TGC CCT AGA AGT TCA CCA TGT GGC ATT TCG ACA CAC ATA		129
Glu Ile Gly His Arg Ala Leu Glu Phe Leu His Leu Gln Asp Gly Ser Ile Asn Tyr Lys		27
GAA ATA GGA CAC AGA GCT CTG GAG TTT CTC CAC CTT CAG GAT GGG AGT ATT AAC TAC AAA		189
Glu Leu Leu Leu Arg His Gln Asp Ala Tyr Gln Ala Gly Ser Val Phe Pro Asp Ser Phe		47
GAG CTG TTA CTT AGG CAC CAG GAT GCA TAT CAG GCT GGA TCC GTG TTT CCT GAC TCA TTT		249
Tyr Pro Ser Ile Cys Glu Arg Gly Gln Phe His Asp Val Ser Glu Ser Thr His Trp Thr		67
TAC CCT AGC ATC TGT GAG AGA GGA CAA TTC CAT GAC GTG TCA GAG AGC ACT CAC TGG ACT		309
Pro Phe Leu Asn Ala Ser Val His Tyr Ile Arg Lys Asn Tyr Pro Leu Pro Trp Asp Glu		87
CCA TTT CTT AAC GCA AGT GTT CAT TAT ATC CGG AAG AAC TAT CCT CTT CCC TGG GAT GAG		369
Asp Thr Glu Lys Leu Val Ala Phe Leu Phe Gly Ile Thr Ser His Met Val Ala Asp Val		107
GAC ACA GAG AAA TTG GTA GCT TTC TTG TTT GGA ATT ACG TCT CAC ATG GTG GCT GAT GTC		429
Asn Trp His Ser Leu Gly Ile Glu Gln Gly Phe Leu Arg Thr Met Ala Ala Ile Asp Phe		127
AAC TGG CAT AGC CTG GGT ATT GAA CAA GGA TTC CTT AGG ACG ATG GCT GCC ATT CAT TTT		489
His Asn Ser Tyr Pro Glu Ala His Pro Ala Gly Asp Phe Gly Gly Asp Val Leu Ser Gln		147
CAC AAC TCC TAT CCC GAG GCA CAT CCG GCT GGT GAT TTC GGA GGA GAC GTG TTG AGC CAG		549
Phe Glu Phe Lys Phe Asn Tyr Leu Ser Arg His Trp Tyr Val Pro Ala Glu Asp Leu Leu		167
TTC GAG TTT AAA TTT AAT TAC CTC TCA CGG CAC TGG TAT GTG CCT GCT GAA GAT CTC CTG		609
Gly Ile Tyr Arg Glu Leu Tyr Gly Arg Ile Val Ile Thr Lys Lys Ala Ile Val Asp Cys		187
GGA ATT TAT AGA GAA CTC TAC GGC CGA ATA GTC ATC ACC AAA AAA GCC ATT GTT GAC TGT		669
Ser Tyr Leu Gln Phe Leu Glu Met Tyr Ala Glu Met Leu Ala Ile Ser Lys Leu Tyr Pro		207
TCA TAC CTT CAA TTC TTG GAA ATG TAT GCG GAG ATG TTA GCT ATT TCC AAG CTT TAT CCC		729
Thr Tyr Ser Val Lys Ser Pro Phe Leu Val Glu Gln Phe Gln Glu Tyr Phe Leu Gly Gly		227
ACT TAT TCT GTA AAA TCC CCA TTT TTG GTG GAA CAA TTT CAA GAA TAC TTC CTA GGA GGG		789
Leu Glu Asp Met Ala Phe Trp Ser Thr Asn Ile Tyr His Leu Thr Ser Tyr Met Leu Lys		247
CTG GAA GAT ATG GCG TTT TGG TCC ACT AAT ATT TAC CAT CTG ACA AGT TAC ATG TTA AAG		849
Asn Gly Thr Ser Asn Cys Asn Leu Pro Glu Asn Pro Leu Phe Ile Thr Cys Gly Gly Gln		267
AAC GGG ACC AGT AAC TGC AAC CTC CCT GAG AAC CCT CTG TTC ATC ACA TGT GGC GGT CAA		909
Gln Asn Asn Thr His Gly Ser Lys Val Gln Lys Asn Gly Phe His Lys Asn Val Thr Ala		287
CAA AAC AAC ACC CAT GGC TCA AAA GTA CAG AAA AAT GGT TTT CAT AAA AAT GTG ACT GCA		969
Ala Leu Thr Lys Asn Ile Gly Lys His Ile Asn Tyr Thr Lys Arg Gly Val Phe Phe Ser		307
GCC CTA ACT AAA AAT ATT GCA AAG CAT ATA AAC TAT ACC AAA AGA GGA GTG TTC TTT AGT		1029
Val Asp Ser Trp Thr Met Asp Phe Leu Ser Phe Met Tyr Lys Ser Leu Glu Arg Ser Ile		327
GTG GAT TCC TGG ACC ATG GAT TCC TTA TCC TTC ATG TAC AAG TCT TTG GAG AGG AGT ATA		1089
Arg Glu Met Phe Ile Gly Ser Ser Gln Pro Leu Thr His Val Ser Ser Pro Ala Ala Ser		347
CGG GAG ATG TTT ATT GGC AGC TCT CAG CCA CTG ACA CAT GTT TCT AGC CCC GCA GCA TCT		1149
Tyr Tyr Leu Ser Phe Pro Tyr Thr Arg Leu Gly Trp Ala Met Thr Ser Ala Asp Leu Asn		367
TAC TAC TTG TCA TTT CCC TAC ACA AGG CTT GGT TGG GCA ATG ACT TCA GCT GAT CTC AAC		1209
Gln Asp Gly Tyr Gly Asp Leu Val Val Gly Ala Pro Gly Tyr Ser His Pro Gly Arg Ile		387
CAG GAT GGA TAC GGT GAC CTG GTG GTG GGT GCC CCT GGC TAC AGC CAC CCA GGC CGC ATT		1269
His Val Gly Arg Val Tyr Leu Ile Tyr Gly Asn Asp Leu Gly Leu Pro Arg Ile Asp Leu		407
CAC GTG GCG CGC GTG TAC CTC ATC TAT GGC AAT GAC CTG GGC TTG CCC CGT ATC GAC CTG		1329
Asp Leu Asp Lys Glu Ala His Gly Ile Leu Glu Gly Phe Gln Pro Ser Gly Arg Phe Gly		427
GAC CTG GAC AAG GAG GCC CAC CGG ATC CTG GAG GGT TTC CAG CCC TCA GGT CCA TTT GGC		1389

FIG 5 (continued)

Ser	Ala	Val	Ala	Val	Leu	Asp	Phe	Asn	Val	Asp	Gly	Val	Pro	Asp	Leu	Ala	Val	Gly	Ala	447
TCC	GCT	GTG	GCT	GTG	CTA	GAC	TTT	AAC	GTG	GAT	GGC	GTG	CCT	GAC	CTG	GCG	GTG	GGA	GCC	1449
Pro	Ser	Val	Gly	Ser	Glu	Lys	Leu	Thr	Tyr	Thr	Gly	Ala	Val	Tyr	Val	Tyr	Phe	Gly	Ser	467
CCC	TGG	GTG	GGC	TCC	GAG	AAG	CTC	ACA	TAC	ACA	GGT	GCA	GTG	TAT	GTG	TAC	TTC	GGT	TCC	1509
Lys	Gln	Gly	Gln	Leu	Ser	Ser	Ser	Pro	Asn	Val	Thr	Ile	Ser	Cys	Gln	Asp	Thr	Tyr	Cys	487
AAA	CAA	GGA	CAA	CTA	TCT	TCT	TCC	CCC	AAC	GTG	ACC	ATC	TCT	TGC	CAG	GAT	ACC	TAC	TGT	1569
Asn	Leu	Gly	Trp	Thr	Leu	Leu	Ala	Ala	Asp	Val	Asn	Gly	Asp	Ser	Glu	Pro	Asp	Leu	Val	507
AAC	TTG	GGC	TGG	ACC	CTC	CTG	GCG	GCA	GAT	GTG	AAT	GGA	GAT	AGT	GAA	CCG	GAC	CTG	GTG	1629
Ile	Gly	Ser	Pro	Phe	Ala	Phe	Gly	Gly	Gly	Lys	Gln	Lys	Gly	Ile	Val	Ala	Ala	Phe	Tyr	527
ATT	GGC	TCC	CCT	TTT	GCT	CCA	GGT	GGA	GGG	AAA	CAG	AAG	GGA	ATT	GTG	GCT	GCA	TTT	TAC	1689
Ser	Gly	Ser	Ser	Tyr	Ser	Ser	Arg	Glu	Lys	Leu	Asn	Val	Glu	Ala	Ala	Asn	Trp	Met	Val	547
TCT	GGC	TCC	AGT	TAC	AGC	AGC	CGA	CAA	AAG	CTG	AAT	GTG	CAG	GCT	CCC	AAC	TGG	ATG	GTG	1749
Lys	Gly	Glu	Glu	Asp	Phe	Ala	Trp	Leu	Gly	Tyr	Ser	Leu	His	Gly	Val	Asn	Val	Asn	Asn	567
AAA	GGC	CAG	CAG	GAC	TTT	GCT	TGG	TTG	GGG	TAC	TCC	CTT	CAC	GGT	GTG	AAT	GTG	AAC	AAC	1809
Arg	Thr	Leu	Leu	Leu	Ala	Gly	Ser	Pro	Thr	Trp	Lys	Asp	Thr	Ser	Ser	Gln	Gly	His	Leu	587
AGG	ACT	TTG	CTC	CTG	GCT	GGA	AGC	CCG	ACC	TGG	AAG	GAC	ACC	AGT	AGT	CAG	GGC	CAC	TTG	1869
Phe	Arg	Thr	Arg	Asp	Glu	Lys	Gln	Ser	Pro	Gly	Arg	Val	Tyr	Gly	Tyr	Phe	Pro	Pro	Ile	607
TTG	CGC	ACT	CGT	GAT	GAG	AAA	CAG	AGC	CCT	GGA	CGG	GTG	TAC	GGC	TAT	TTC	CCG	CCA	ATC	1929
Cys	Gln	Ser	Trp	Phe	Thr	Ile	Ser	Gly	Asp	Lys	Ala	Met	Gly	Lys	Leu	Gly	Thr	Ser	Leu	627
TGT	CAA	AGC	TGG	TTT	ACC	ATT	TCC	GGA	GAC	AAG	GCA	ATG	GGG	AAA	CTG	GGT	ACC	TCC	CTG	1989
Ser	Ser	Gly	His	Val	Ile	Val	Asn	Gly	Thr	Arg	Thr	Gln	Val	Leu	Leu	Val	Gly	Ala	Pro	647
TCT	AGT	GGC	CAC	GTG	ATG	GTG	AAC	GGG	ACC	CCG	ACC	CAA	GTG	CTG	CTG	GTG	GGG	GCC	CCG	2049
Thr	Gln	Asp	Val	Val	Ser	Lys	Val	Ser	Phe	Leu	Thr	Met	Thr	Leu	His	Gln	Gly	Gly	Ser	667
ACT	CAA	GAT	GTG	GTG	TCT	AAG	GTA	TCA	TTC	CTG	ACC	ATG	ACC	CTG	CAC	CAA	GGT	GGG	AGC	2109
Thr	Arg	Met	Tyr	Glu	Leu	Thr	Pro	Asp	Ser	Gln	Pro	Ser	Leu	Leu	Ser	Thr	Phe	Ser	Gly	687
ACT	CGG	ATG	TAT	GAA	CTG	ACA	CCT	GAC	TCA	CAG	CCT	TCT	CTG	CTC	AGC	ACC	TTC	AGT	GGA	2169
Asn	Arg	Arg	Phe	Ser	Arg	Phe	Gly	Gly	Val	Leu	His	Leu	Ser	Asp	Leu	Asp	Asn	Asp	Gly	707
AAC	CGC	CGC	TTG	TCC	CGA	TTT	GGT	GGC	GTT	CTG	CAC	TTG	AGT	GAC	TTG	GAT	AAT	GAT	GGC	2229
Leu	Asp	Glu	Ile	Ile	Val	Ala	Ala	Pro	Leu	Arg	Ile	Thr	Asp	Ala	Thr	Ala	Gly	Leu	Met	727
TTA	GAT	GAA	ATC	ATC	GTA	GCA	GCC	CCG	CTG	AGG	ATC	ACA	GAC	GCA	ACT	GCG	GGA	CTG	ATG	2289
Gly	Glu	Glu	Asp	Gly	Arg	Val	Tyr	Val	Phe	Asn	Gly	Lys	Gln	Ile	Thr	Val	Gly	Asp	Val	747
GGG	GAA	GAG	GAT	GGC	CGT	GTT	TAT	GTG	TTT	AAT	GCC	AAA	CAG	ATC	ACC	GTG	GGT	GAC	GTG	2349
Thr	Gly	Lys	Cys	Lys	Ser	Trp	Val	Thr	Pro	Cys	Pro	Glu	Glu	Lys	Ala	Gln	Tyr	Val	Leu	767
ACA	GGC	AAA	TGC	AAA	TCA	TGG	GTA	ACT	CCG	TGT	CCA	GAA	GAA	AAG	GCC	CAA	TAT	GTA	CTA	2409
Ile	Ser	Pro	Glu	Ala	Gly	Ser	Arg	Phe	Gly	Ser	Ser	Val	Ile	Thr	Val	Arg	Ser	Lys	Glu	787
ATT	TCT	CCT	GAA	GCA	GGC	TCA	AGG	TTT	GGG	AGC	TCT	GTG	ATC	ACT	GTG	AGG	TCC	AAG	GAA	2469
Lys	Asn	Gln	Val	Ile	Ile	Ala	Ala	Gly	Arg	Ser	Ser	Leu	Gly	Ala	Arg	Leu	Ser	Gly	Val	807
AAG	AAT	CAA	GTG	ATC	ATT	GCT	GCT	GGA	AGG	AGT	TCT	CTG	GGA	GCC	CGA	CTC	TCT	GGG	GTG	2529
Leu	His	Ile	Tyr	Arg	Leu	Gly	Gln	Asp	End											816
CTT	CAT	ATC	TAT	AGG	CTC	GCC	CAA	GAT	TAA	AGGTTTCACTCCATTTTCC										2578

FIG 6




FIG 7




FIG 8




FIG 9

Nucleotide sequence and deduced amino acid sequence of
Human Liver GPI-Phospholipase D cDNA

```

      1
cgtcattagaggagccggtggggaatgagagcATGTCTGCTTTCAGGTTGTGGCCCGGCC
-----+-----+-----+-----+-----+-----+-----+-----+ 28
gcagtaatctcctcggccaccccttactctcgTACAGACGAAAGTCCAACACCGGGCCGG
      -24
      M S A F R L W P G L -15

TGCTGATGATCGTGATGGCTTCTCTCTGCCATAGAGGTTTCATCGTGTGGCCTTTC AACGC
-----+-----+-----+-----+-----+-----+-----+-----+ 88
ACGACTACTAGCACTACCGAAGAGAGACGGTATCTCCAAGTAGCACACCGGAAAGTTGCG
      +1
      L M I V M A S L C H R G S S C G L S T H +6

ACATAGAAATCGGACACAGAGCTCTGGAGTTTCTTCATCTTCACAATGGGCATGTTAACT
-----+-----+-----+-----+-----+-----+-----+-----+ 148
TGTATCTTTAGCCTGTGTCTCGAGACCTCAAAGAAGTAGAAGTGTTACCCGTACAATTGA
      +1
      I E I G H R A L E F L H L H N G H V N Y 26

ACAAAGAGCTGTTACTAGAACACCAGGATGCATATCAGGCTGGAACCGTGTTTCCTGATT
-----+-----+-----+-----+-----+-----+-----+-----+ 208
TGTTTCTCGACAATGATCTTGTGGTCCTACGTATAGTCCGACCTTGGCACAAGGACTAA
      +1
      K E L L L E H Q D A Y Q A G T V F P D C 46

GTTTTTACCCTAGCCTCTGCAAAGGAGGAAAAATTCATGATGTGTCTGAGAGCACTCACT
-----+-----+-----+-----+-----+-----+-----+-----+ 268
CAAAAATGGGATCGGAGACGTTTCTCCTCTTTTAAGGTACTACACAGACTCTCGTGAGTGA
      +1
      F Y P S L C K G G K F H D V S E S T H W 66

GGACTCCGTTTCTTAACGCAAGCGTTCATTATATCCGAGAGAACTATCCCCTTCCCTGGG
-----+-----+-----+-----+-----+-----+-----+-----+ 328
CCTGAGGCAAAGAATTGCGTTCGCAAGTAATATAGGCTCTCTTGATAGGGGAAGGGACCC
      +1
      T P F L N A S V H Y I R E N Y P L P W E 86

AGAAGGACACAGAGAACTGGTAGCTTTCTTGTTTGGGAATTACTTCTCATATGGTAGCAG
-----+-----+-----+-----+-----+-----+-----+-----+ 388
TCTTCCTGTGTCTCTTTGACCATCGAAAGAACAACCTTAATGAAGAGTATACCATCGTC
      +1
      K D T E K L V A F L F G I T S H M V A D 106

```

FIG 9 (continued)

ATGTCAGCTGGCATAGTCTGGGCATTGAACAAGGATTCCTTAGGACCATGGGAGCTATTG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 448
 TACAGTCGACCGTATCAGACCCGTAACCTTGTTCTAAGGAATCCTGGTACCCTCGATAAC
 V S W H S L G I E Q G F L R T M G A I D 126
 ATTTTCACGGCTCCTATTCTGAGGCTCATTTCAGCTGGTGATTTTGGAGGAGATGTGTTGA
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 508
 TAAAAGTGCCGAGGATAAGACTCCGAGTAAGTCGACCACTAAAACCTCCTCTACACAAC
 F H G S Y S E A H S A G D F G G D V L S 146
 GCCAGTTTGAATTTAATTTTAATTACCTTGCACGACGCTGGTATGTGCCAGTCAAAGATC
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 568
 CGGTCAAACCTTAAATTTAAATTAATGGAACGTGCTGCGACCATAACGGTCAGTTTCTAG
 Q F E F N F N Y L A R R W Y V P V K D L 166
 TGCTGGGAATTTATGAGAACTCTATGGTCGAGAAGTCATCACTGAAAATGTAATTGTTG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 628
 ACGACCTTAAATACTCTTTGAGATACCAGCTCTTCAGTAGTGACTTTTACATTAACAAC
 L G I Y E K L Y G R E V I T E N V I V D 186
 ATTGTTACATATCCAGTTCTTAGAAATGTATGGTGAGATGCTAGCTGTTTCCAAGTTAT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 688
 TAACAAGTGTATAGGTCAAGAATCTTTACATACCACTCTACGATCGACAAAGGTTCAATA
 C S H I Q F L E M Y G E M L A V S K L Y 206
 ATCCCTCTTACTCTACAAAGTCCCCGTTTTTGGTGGAACAATTCCAAGAGTATTTTCTTG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 748
 TAGGGAGAATGAGATGTTTCAGGGGCAAAAACCACCTTGTTAAGGTTCTCATAAAAGAAC
 P S Y S T K S P F L V E Q F Q E Y F L G 226
 GAGGACTGGATGATATGGCGTTTTTGGTCCACTAATATTTACCATCTAACGAGCTTCATGT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 808
 CTCCTGACCTACTATACCGCAAAACCAGGTGATTATAAATGGTAGATTGCTCGAAGTACA
 G L D D M A F W S T N I Y H L T S F M L 246
 TGGAGAATGGGACCAGTGAAGTGCAGCCTACCTGAGAACCCTCTGTTTCATTGCATGTGGTG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 868
 ACCTCTTACCCTGGTCACTGACGTCGGATGGACTCTTGGGAGACAAGTAACGTACACCAC
 E N G T S D C S L P E N P L F I A C G G 266
 GCCAGCAAAACCACACCCAGGGCTCGAAAATGCAGAAAATGATTTTCACAGAAATTTGA
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 928
 CGGTGCTTTTGGTGTGGGTCCCGAGCTTTTACGTCTTTTACTAAAAGTGTCTTTAAACT
 Q Q N H T Q G S K M Q K N D F H R N L T 286

FIG 9 (continued)

```

CTTCATCCCTAACTGAAAACATTGACAGGAATATAAACTATAACCGAAAGAGGAGTGTTCCT
-----+-----+-----+-----+-----+-----+-----+ 988
GAAGTAGGGATTGACTTTTGTAACTGTCCTTATATTTGATATGGCTTTCTCCTCACAAGA

  S  S  L  T  E  N  I  D  R  N  I  N  Y  T  E  R  G  V  F  F  306

TCAGTGTAATTCCTGGACCCCGGATTCCATGTCCTTTATCTACAAGGCTTTGGAAAGGA
-----+-----+-----+-----+-----+-----+ 1048
AGTCACATTTAAGGACCTGGGGCCTAAGGTACAGGAAATAGATGTTCCGAAACCTTTCTCT

  S  V  N  S  W  T  P  D  S  M  S  F  I  Y  K  A  L  E  R  N  326

ACGTAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTACAGAAGCACATCTCTAGCCCT
-----+-----+-----+-----+-----+-----+ 1108
TGCATTCTGTGTTACAAGTATCCACCGAGAGTCAACAGTGTCTTCGTGTAGAGATCGGGGA

  V  R  T  M  F  I  G  G  S  Q  L  S  Q  K  H  I  S  S  P  L  346

TAGCATCTTACTTCTTGTCATTTTCCTTATGCAAGGCTTGGCTGGGCAATGACCTCAGCTG
-----+-----+-----+-----+-----+-----+ 1168
ATCGTAGAATGAAGAACAGTAAAGGAATACGTTCCGAACCGACCCGTTACTGGAGTCGAC

  A  S  Y  F  L  S  F  P  Y  A  R  L  G  W  A  M  T  S  A  D  366

ACCTCAACCAGGATGGGTACGGCGACCTCGTGGTGGGCGCACCAGGCTACAGCCGCCCTG
-----+-----+-----+-----+-----+-----+ 1228
TGGAGTTGGTCTTACCCATGCCGCTGGAGCACCACCCGCGTGGTCCGATGTCGGCGGGAC

  L  N  Q  D  G  Y  G  D  L  V  V  G  A  P  G  Y  S  R  P  G  386

GCCGCATCCACATCGGGCGCGTGTACCTCATCTACGGCAATGAACTGGGTCTGCCGCCCG
-----+-----+-----+-----+-----+-----+ 1288
CGGCGTAGGTGTAGCCCGCGCACATGGAGTAGATGCCGTTACTTGACCCAGACGGCGGGC

  R  I  H  I  G  R  V  Y  L  I  Y  G  N  E  L  G  L  P  P  V  406

TTGACCTGGACCTGGACAAGGAGGCCACGGGATCCTTGAAGGTTTCCAGCCCTCAGGTC
-----+-----+-----+-----+-----+-----+ 1348
AACTGGACCTGGACCTGTTCTCCGGGTGCCCTAGGAACTTCCAAAGGTCGGGAGTCCAG

  D  L  D  L  D  K  E  A  H  G  I  L  E  G  F  Q  P  S  G  R  426

GGTTTGGCTCGGCCTTGGCTATGTTGGACTTTAACATGGATGGCGTGCCTGACCTGGCCG
-----+-----+-----+-----+-----+-----+ 1408
CCAAACCGAGCCGGAACCGATACAACCTGAAATTGTACCTACCGCACGGACTGGACCGGC

  F  G  S  A  L  A  M  L  D  F  N  M  D  G  V  P  D  L  A  V  446

TGGGAGCTCCCTCGGTGGGCTCTGAGCAGCTCACCTACAAAGGTGCTGTGTATGTCTACT
-----+-----+-----+-----+-----+-----+ 1468
ACCCTCGAGGGAGCCACCCGAGACTCGTCGAGTGGATGTTTCCACGACACATACAGATGA

  G  A  P  S  V  G  S  E  Q  L  T  Y  K  G  A  V  Y  V  Y  F  466

```

FIG 9 (continued)

```

TGGTTCCAAACAAGGAAGAATGTCTTCTTCCCCTAACATCACCATCTCTTGCCAGGACA
-----+-----+-----+-----+-----+-----+-----+-----+ 1528
AACCAAGGTTTGTTCCTTCTTACAGAAGAAGGGGATTGTAGTGGTAGAGAACGGTCCTGT
    G  S  K  Q  G  R  M  S  S  S  P  N  I  T  I  S  C  Q  D  I  486
TCTACTGTAACCTTGGGCTGGACTCTCTTGGCTGCAGATGTGAATGGAGACAGTGAGCCCC
-----+-----+-----+-----+-----+-----+-----+-----+ 1588
CATGACATTGAACCCGACCTGAGAGAACCGACGTCTACACTTACCTCTGTCACTCGGGC
    Y  C  N  L  G  W  T  L  L  A  A  D  V  N  G  D  S  E  P  D  506
TCTGGTCATTGGCTCCCTTTTGCACCAGGTGGAGGGAAGCAGAAGGGAATTGTGGCTG
-----+-----+-----+-----+-----+-----+-----+-----+ 1648
TAGACCAGTAACCGAGGGGAAAACGTGGTCCACCTCCCTTCGTCTTCCCTTAACACCGAC
    L  V  I  G  S  P  F  A  P  G  G  G  K  Q  K  G  I  V  A  A  526
TTTTTTATTCTGGCCCCAGCCTGAGCAACAAAGAGAAACTGAACGTGGAGGCGGCCAACT
-----+-----+-----+-----+-----+-----+-----+-----+ 1708
CAAAATAAGACCGGGGTCGGACTCGTTGTTTCTCTTTGACTTGCACCTCCGCCGGTTGA
    F  Y  S  G  P  S  L  S  N  K  E  K  L  N  V  E  A  A  N  W  546
ACGGTGAGAGGCGAGGAAGACTTTGCCTGGTTTGGATACTCCCTTCACGGTGTCAGTG
-----+-----+-----+-----+-----+-----+-----+-----+ 1768
TGCCACTCTCCGCTCCTTCTGAAACGGACCAAACCTATGAGGGAAGTGCCACAGTGAC
    T  V  R  G  E  E  D  F  A  W  F  G  Y  S  L  H  G  V  T  V  566
TGACAACAGAACCTTGCTGCTGGTTGGGAGCCCGACCTGGAAGAATGCCAGCAGGCTGG
-----+-----+-----+-----+-----+-----+-----+-----+ 1828
ACCTGTTGTCTTGGAACGACGACCAACCCTCGGGCTGGACCTTCTTACGGTCGTCCGACC
    D  N  R  T  L  L  L  V  G  S  P  T  W  K  N  A  S  R  L  G  586
CCGTTTGTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGGGTGTATGGCTACTTCC
-----+-----+-----+-----+-----+-----+-----+-----+ 1888
CGCAAACAATGTGTAGGCTCTACTCTTTTCTCGGAACCCTCCACATACCGATGAAGG
    R  L  L  H  I  R  D  E  K  K  S  L  G  R  V  Y  G  Y  F  P  606
CACCAAACAGCCAAAGCTGGTTTACCATTGTTGGAGACAAGGCAATGGGGAAACTGGGTA
-----+-----+-----+-----+-----+-----+-----+-----+ 1948
TGTTTGTGCGGTTTCGACCAAATGGTAACAACCTCTGTTCCGTTACCCCTTTGACCCAT
    P  N  S  Q  S  W  F  T  I  V  G  D  K  A  M  G  K  L  G  T  626
TTCCTGTCCAGTGGCCACGTGCTGATGAATGGAACCTCTGACCCAGGTGCTGCTGGTGG
-----+-----+-----+-----+-----+-----+-----+-----+ 2008
AAGGGACAGGTCACCGGTGCACGACTACTTACCTTGAGACTGGGTCCACGACGACCACC
    S  L  S  S  G  H  V  L  M  N  G  T  L  T  Q  V  L  L  V  G  646

```

FIG 9 (continued)

```

GAGCCCCGACACGTGATGATGTGTCTAAGATGGCATTCCCTGACCATGACCCTGCACCAAG
-----+-----+-----+-----+-----+-----+ 2068
CTCGGGGCTGTGCACTACTACACAGATTCTACCGTAAGGACTGGTACTGGGACGTGGTTC
  A P T R D D V S K M A F L T M T L H Q G 666
GCGGAGCCACTCGGATGTACGCGCTCACATCCGACCTGCAGCCACCGCTGCTCAGCACCT
-----+-----+-----+-----+-----+ 2128
CGCCTCGGTGAGCCTACATGCGCGAGTGTAGGCTGGACGTCGGTGGCGACGAGTCGTGGA
  G A T R M Y A L T S D L Q P P L L S T F 686
TCAGCGGAGACCGCCGCTTCTCTCGATTGTTGGTGGCGTTCTGCACTTGAGTGACCTGGATG
-----+-----+-----+-----+-----+ 2188
AGTCGCCTCTGGCGGCCAAGAGAGCTAAACCACCGCAAGACGTGAACTCACTGGACCTAC
  S G D R R F S R F G G V L H L S D L D D 706
ATGATGGCGTAGATGAAATCATCGTGGCAGCCCCCTGAGGATAGCAGATGTAACCTCTG
-----+-----+-----+-----+-----+ 2248
TACTACCGCATCTACTTTAGTAGCACCGTCGGGGGGACTCCTATCGTCTACATTGGAGAC
  D G V D E I I V A A P L R I A D V T S G 726
GGCTGATTGGGGGAGAAGATGGCCGAGTTTATGTATATAATGGCAAAGAGACCACCCTTG
-----+-----+-----+-----+-----+ 2308
CCGACTAACCCCTCTTCTACCGGCTCAAATACATATATTACCGTTTCTCTGGTGGGAAC
  L I G G E D G R V Y V Y N G K E T T L G 746
GTGACATGACTGGCAAATGCAAATCGTGGATGACTCCATGTCCAGAAGAAAAGGCCCAAT
-----+-----+-----+-----+-----+ 2368
CACTGTACTGACCGTTTACGTTTAGCACCTACTGAGGTACAGGTCTTCTTTCCGGGTTA
  D M T G K C K S W M T P C P E E K A Q Y 766
ATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCCCTGATCACCGTGAGGT
-----+-----+-----+-----+-----+ 2428
TACATAACTAAAGAGGACTTCGGTTCGAGTTCCAAACCCTCGAGGGACTAGTGGCACTCCA
  V L I S P E A S S R F G S S L I T V R S 786
CCAAGGCAAAGAATCAAGTCGTCATTGCCGCTGGAAGGAGCTCTTTGGGAGCCCGACTCT
-----+-----+-----+-----+-----+ 2488
GGTTCCGTTTCTTAGTTTCAGCAGTAACGGCGACCTTCCTCGAGAAACCCTCGGGCTGAGA
  K A K N Q V V I A A G R S S L G A R L S 806
CCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGA
-----+-----+-----+-----+-----+ 2526
GGCCCCGTGAAGTGCAGATATCGGAACCGAGTCTAACT

```

FIG 10

Alignment of deduced amino acid sequence of
Human and Bovine Liver GPI-Phospholipase D

	-24					25
Bovine	MSAFRFWSGL	LMLL.GFLCP	RSSP.CGIST	HIEIGHRALE	FLHLQDGSIN	
Human	MSAFRLWPGL	LMIVMASLCH	RGSS.CGLST	HIEIGHRALE	FLHLHNGHVN	
	MSAFR.W.GL	LM.....LC.	R.S..CG.ST	HIEIGHRALE	FLHL..G..N	
	26					75
Bovine	YKELLRLHQD	AYQAGSVFPD	SFYPSICERG	QFHDVSESTH	WTPFLNASVH	
Human	YKELLLEHQD	AYQAGTVFPD	CFYPSLCKGG	KFHDVSESTH	WTPFLNASVH	
	YKELL.L.HQD	AYQAG.VFPD	.FYPS.C..G	.FHDVSESTH	WTPFLNASVH	
	76					125
Bovine	YIRKNYPLPW	DEDTEKLVAE	LFGITSHMVA	DVNWHSLGIE	QGFLRTMAAI	
Human	YIRENYPLPW	EKDTEKLVAE	LFGITSHMVA	DVSWHSLGIE	QGFLRTMGAI	
	YIR.NYPLPW	..DTEKLVAE	LFGITSHMVA	DV.WHSLGIE	QGFLRTM.AI	
	126					175
Bovine	DFHNSYPEAH	PAGDFGGDVL	SQFEFKFNYL	SRHWYVPAED	LLGIYRELYG	
Human	DFHGSYSEAH	SAGDFGGDVL	SQFEFNFNYL	ARRWYVPVKD	LLGIYEKLYG	
	DFH.SY.EAH	.AGDFGGDVL	SQFEF.FNYL	.R.WYVP..D	LLGIY..LYG	
	176					225
Bovine	RIVITKKAIV	DCSYLQFLEV	YAEMLAISKL	YPTYSVKSPF	LVEQFQEYFL	
Human	REVITENVIV	DCSHIQFLEM	YGEMLAIVSKL	YPSYSTKSPF	LVEQFQEYFL	
	R.VIT...IV	DCS...QFLE.	Y.EMLA.SKL	YP.YS.KSPF	LVEQFQEYFL	
	226					275
Bovine	GGLEDMAFWS	TNIYHLTSYM	LKNGTSNCNL	PENPLFITCG	GQQNNTHGSK	
Human	GGLDDMAFWS	TNIYHLTSFM	LENGTSDCSL	PENPLFIACG	GQQNHTQGSK	
	GGL.DMAFWS	TNIYHLTS.M	L.NGTS.C.L	PENPLFI.CG	GQQN.T.GSK	
	276					325
Bovine	VQKNGFHKNV	TAALTKNIGK	HINYTKRGVF	FSVDSWTMDS	LSFMYKSLEK	
Human	MQKNDFHRNL	TSSLTENIDR	NINYTERGVF	FSVNSWTPDS	MSFIYKALER	
	.QKN.FH.N.	T..LT.NI..	.INYT.RGVF	FSV.SWT.DS	.SF.YK.LER	
	326					375
Bovine	SIREMFIGSS	Q.PLTHVSSP	AASYLSFPY	TRLGWAMTSA	DLNQDGYGDL	
Human	NVRTMFIGGS	QLSQKHISSP	LASYFLSFPY	ARLGWAMTSA	DLNQDGYGDL	
	..R.MFIG.S	Q....H.SSP	.ASY.LSFPY	.RLGWAMTSA	DLNQDGYGDL	
	376					425
Bovine	VVGAPGYSHP	GRIHVGRVYL	IYGNDLGLPR	IDLDLDKEAH	GILEGFQPSG	
Human	VVGAPGYSRP	GRIHIGRVYL	IYGNEIGLPP	VDLDLDKEAH	GILEGFQPSG	
	VVGAPGYS.P	GRIH.GRVYL	IYGN.LGLP.	.DLLDLDKEAH	GILEGFQPSG	

FIG 10 (continued)

	426				475
Bovine	RFGSAVAVLD	FNVDGVPDLA	VGAPSVGSEK	LTYTGAVYVY	FGSKQGQLSS
Human	RFGSALAMLD	FNMDGVPDLA	VGAPSVGSEQ	LTYKGAVYVY	FGSKQGRMSS
	RFGSA.A.LD	FN.DGVPDLA	VGAPSVGSE.	LTY.GAVYVY	FGSKQG..SS
	476				525
Bovine	SPNVTISCQD	TYCNLGWTL	AADVNGDSEP	DLVIGSPFAP	GGGKQKGIVA
Human	SPNITISCQD	IYCNLGWTL	AADVNGDSEP	DLVIGSPFAP	GGGKQKGIVA
	SPN.TISCQD	.YCNLGWTL	AADVNGDSEP	DLVIGSPFAP	GGGKQKGIVA
	526				575
Bovine	AFYSGSSYSS	REKLNVEAAN	WMVKGEEDFA	WLGYSLHGVN	VNNRTLLLAG
Human	AFYSGPSLSN	KEKLNVEAAN	WTVRGEEDFA	WFGYSLHGVN	VDNRTLLLVG
	AFYSG.S.S.	.EKLNVEAAN	W.V.GEEDFA	W.GYSLHGV.	V.NRTLL.LG
	576				625
Bovine	SPTWKDTSSQ	GHLFTRDEK	QSPGRVYGYF	PPICQSWFTI	SGDKAMGKLG
Human	SPTWKNASRL	GRLHIRDEK	KSLGRVYGYF	PPNSQSWFTI	VGDKAMGKLG
	SPTWK..S..	G.L...RDEK	.S.GRVYGYF	PP..QSWFTI	.GDKAMGKLG
	626				675
Bovine	TSLSSGHVMV	NGTRTQVLLV	GAPTQDVVSK	VSFLTMTLHQ	GGSTRMYELT
Human	TSLSSGHVLM	NGTLTQVLLV	GAPTRDDVSK	MAFLTMTLHQ	GGATRMAYLT
	TSLSSGHV..	NGT.TQVLLV	GAPT.D.VSK	...FLTMTLHQ	GG.TRM.Y.LT
	676				725
Bovine	PDSQPSLLST	FSGNRRFSRF	GGVLHLSDL	NDGLDEIIVA	APLRITDATA
Human	SDLQPPLLST	FSGDRRFSRF	GGVLHLSDL	DDGVDEIIVA	APLRIADVTS
	.D.QP.LLST	FSG.RRFSRF	GGVLHLSDL	.DG.DEIIVA	APLRI.D.T.
	726				775
Bovine	GLMGEEDGRV	YVFNGKQITV	GDVTGKCKSW	VTPCPEEKAQ	YVLISPEAGS
Human	GLIGGEDGRV	YVYNGKETTL	GDMTGKCKSW	MTPCPEEKAQ	YVLISPEASS
	GL.G.EDGRV	YV.NGK..T.	GD.TGKCKSW	.TPCPEEKAQ	YVLISPEA.S
	776				817
Bovine	RFGSSVITVR	SKEKNQVIA	AGRSSLGARL	SGVLHIYRLG	QD*
Human	RFGSSLITVR	SKAKNQVIA	AGRSSLGARL	SGALHVYSLG	SD*
	RFGSS.ITVR	SK.KNQV.IA	AGRSSLGARL	SG.LH.Y.LG	.D*

FIG 11

The Nucleotide Sequence and Amino Acid Sequence of the Human
Pancreatic Glycosyl Phosphatidyl Inositol Specific-Phospholipase D.

1	GACAGTGAACCCGATCTGGTCATCGGCTCCCTTTTGCACCAGGTGGAGGGAAGCAGAAG	60
1	AspSerGluProAspLeuValIleGlySerProPheAlaProGlyGlyGlyLysGlnLys	20
61	GGAAATTGTGGCTGCGTTTTATTCTGGCCCCAGCCCTGAGCGACAAAGAAAACTGAACGTG	120
21	GlyIleValAlaAlaPheTyrSerGlyProSerLeuSerAspLysGluLysLeuAsnVal	40
121	GAGGCAGCCAACTGGACGGTGAGAGGCGAAGAAGACTTCTCCTGGTTTGGATATTCCTT	180
41	GluAlaAlaAsnTrpThrValArgGlyGluGluAspPheSerTrpPheGlyTyrSerLeu	60
181	CACGGTGTCACTGTGACAAACAGAACCTTGCTGTTGGTTGGGAGCCCCACCTGGAAGAAT	240
61	HisGlyValThrValAspAsnArgThrLeuLeuLeuValGlySerProThrTrpLysAsn	80
241	GCCAGCAGGCTGGGCCATTTGTTACACATCCGAGATGAGAAAAAGAGCCTTGGAGGGTGG	300
81	AlaSerArgLeuGlyHisLeuLeuHisIleArgAspGluLysLysSerLeuGlyArgVal	100
301	TATGGCTACTTCCCACCAACGGCCAAAGCTGGTTTACCATTTCTGGAGACAAGGCAATG	360
101	TyrGlyTyrPheProProAsnGlyGlnSerTrpPheThrIleSerGlyAspLysAlaMet	120
361	GGGAAACTGGGTACTTCCCTTTCCAGTGGTCACGTACTGATGAATGGGACTCTGAAACAA	420
121	GlyLysLeuGlyThrSerLeuSerSerGlyHisValLeuMetAsnGlyThrLeuLysGln	140
421	GTGCTGCTGGTTGGAGCCCCCTACGTACGATGACGTGTCTAAGGTGGCATTCTGACCGTG	480
141	ValLeuLeuValGlyAlaProThrTyrAspAspValSerLysValAlaPheLeuThrVal	160
481	ACCCTACACCAAGGCGGAGCCACTCGCGTGTACGCACCTCATATCTGACGCGCAGCCTCTG	540
161	ThrLeuHisGlnGlyGlyAlaThrArgValTyrAlaLeuIleSerAspAlaGlnProLeu	180
541	CTGCTCAGCACCTTCAGCGGAGACCGCGCTTCTCCCGATTTGGTGGCGTTCTGCACTTG	600
181	LeuLeuSerThrPheSerGlyAspArgArgPheSerArgPheGlyGlyValLeuHisLeu	200
601	AGTGACCTGGATGATGATGGCTTAGATGAAATCATCATGCGAGCCCCCTGAGGATAGCA	660
201	SerAspLeuAspAspAspGlyLeuAspGluIleIleMetAlaAlaProLeuArgIleAla	220
661	GATGTAACCTCTGGACTGATTGGGGGAGAAGACGGCCGAGTATATGTATATAATGGCAA	720
221	AspValThrSerGlyLeuIleGlyGlyGluAspGlyArgValTyrValTyrAsnGlyLys	240
721	GAGACCACCTTGGTGACATGACTGGCAAATGCAAATCATESATAACTCCATGTCCAGAA	780
241	GluThrThrLeuGlyAspMetThrGlyLysCysLysSerTrpIleThrProCysProGlu	260
781	GAAAAGGCGCAATATGTATTGATTTCTCCTGAAGCCAGCTCAAGTTTGGGAGCTCCCTC	840
261	GluLysAlaGlnTyrValLeuIleSerProGluAlaSerSerArgPheGlySerSerLeu	280
841	ATCACCGTGAGGTCCAAGGCAAAGAACCAAGTCCTCATTGCTGCTGGAAGGAGTTCTTTG	900
281	IleThrValArgSerLysAlaLysAsnGlnValValIleAlaAlaGlyArgSerSerLeu	300
901	GGAGCCCGACTCTCCGGGGCACTTCACGTCTATAGCCTTGGCTCAGATTGAAGATTTAC	960
301	GlyAlaArgLeuSerGlyAlaLeuHisValTyrSerLeuGlySerAsp	320
961	TGCATTTCCCCACTCTGCCACCTCTCTCATGCTGAATCACATCCATGGTGAGCATTTTG	1020
1021	ATGGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCCTGATAGACATGGGCTCCTG	1080
1081	GGAGTAGAGAGACACACTAACAGCCACACCTCTGGAAATCTGATACAGTAAATATATGA	1140
1141	CTACACCAGAAATATGTGAAATAGCAGACATTCTGCTTACTCATGTCTCCTTCCACAGTT	1200
1201	TACTTCTCTGCTCCCTTTGCATCTAAACCTTTCTTCTTTCCCAACTTATTGCCTGTAGTC	1260

FIG 12




FIG 1




FIG 2




FIG 3




FIG 4




FIG 5

GCATTCTCTCTCCACATAGGACCCGGGCACTAATGAGGCC	Met Ser Ala Phe Arg Phe Trp Ser Gly Leu	-14
ATG TCT GCT TTC AGA TTC TGG TCA GGA CTC		49
Leu Met Leu Leu Gly Phe Leu Cys Pro Arg Ser Ser Pro Cys Gly Ile Ser Thr His Ile	7	
CTG ATG GTA CTG GGC TTC CTC TGC CCT AGA AGT TCA CCA TGT GGC ATT TCG ACA CAC ATA	129	
Glu Ile Gly His Arg Ala Leu Glu Phe Leu His Leu Gln Asp Gly Ser Ile Asn Tyr Lys	27	
GAA ATA GGA CAC AGA GGT CTG GAG TTT CTC CAG CTT CAG CAT GGG AGT ATT AAC TAC AAA	189	
Glu Leu Leu Leu Arg His Gln Asp Ala Tyr Gln Ala Gly Ser Val Phe Pro Asp Ser Phe	47	
GAG CTG TTA CTT AGG CAC CAG CAT GCA TAT CAG GCT GGA TCG GTG TTT CCT GAC TCA TTT	249	
Tyr Pro Ser His Cys Glu Arg Gly Gln Phe His Asp Val Ser Glu Ser Thr His Trp Thr	67	
TAC CCT AGC ATC TGT GAG AGA GGA CAA TTC CAT CAC GTG TCA GAG ACC ACT CAC TCG ACT	309	
Pro Phe Leu Asn Ala Ser Val His Tyr Ile Arg Lys Asn Tyr Pro Leu Pro Trp Asp Glu	87	
CCA TTT CTT AAC GCA AGT GTT CAT TAT ATC GCG AAG AAC TAT CCT CTT CCC TCG GAT GAG	369	
Asp Thr Glu Lys Leu Val Ala Phe Leu Phe Gly Ile Thr Ser His Met Val Ala Asp Val	107	
CAC ACA GAG AAA TTT GTA GGT TTC TTG TTT GGA ATT ACC TCT CAC ATG GTG GCT GAT GTG	429	
Asn Trp His Ser Leu Gly Ile Glu Gln Gly Phe Leu Arg Thr Met Ala Ala Ile Asp Phe	127	
AAC TGG CAT ACC CTC GGT ATT GAA CAA GGA TTC CTT AGG AGG ATG CCT GCG ATT GAT TTT	489	
His Asn Ser Tyr Pro Glu Ala His Pro Ala Gly Asp Phe Gly Gly Asp Val Leu Ser Gln	147	
CAC AAC TCG TAT CCC GAG GCA CAT CCC GCT GGT GAT TTC GGA GGA GAC GTG TTT AGC CAG	549	
Phe Glu Phe Lys Phe Asn Tyr Leu Ser Arg His Trp Tyr Val Pro Ala Glu Asp Leu Leu	167	
TTC GAG TTT AAA TTT AAT TAC CTC TCA GCG CAC TGG TAT GTG CCT GCT GAA CAT CTC CTC	609	
Gly Ile Tyr Arg Glu Leu Tyr Gly Arg Ile Val Ile Thr Lys Lys Ala Ile Val Asp Cys	187	
GGA ATT TAT AGA GAA CTC TAC GCG GGA ATG GTC ATC ACC AAA AAA GCG ATT GTT GAC TGT	669	
Ser Tyr Leu Gln Phe Leu Glu Met Tyr Ala Glu Met Leu Ala Ile Ser Lys Leu Tyr Pro	207	
TCA TAC GTT CAA TTT TTT GAA ATG TAT GCG GAG ATG TTA GCT ATT TCG AAG CTT TAT GCG	729	
Thr Tyr Ser Val Lys Ser Pro Phe Leu Val Glu Gln Phe Gln Glu Tyr Phe Leu Gly Gly	227	
ACT TAT TCT GGA AAA TCC CCA TTT TTT CTC GAA CAA TTT CAA GAA TAC TTC CTA GGA GCG	789	
Leu Glu Asp Met Ala Phe Trp Ser Thr Asn Ile Tyr His Leu Thr Ser Tyr Met Leu Lys	247	
CTG GAA GAT ATG GCG TTT TCG TCC ACT AAT ATT TAC CAT CTG ACA AGT TAC ATG TTA AAG	849	
Asn Gly Thr Ser Asn Cys Asn Leu Pro Glu Asn Pro Leu Phe Ile Thr Cys Gly Gly Gln	267	
AAC GGG ACC AGT AAC TGC AAC CTC CCT GAG AAG CCT CTG TTC ATC ACA TGT GCG GGT CAA	909	
Gln Asn Asn Thr His Gly Ser Lys Val Gln Lys Asn Gly Phe His Lys Asn Val Thr Ala	287	
CAA AAC AAC ACC CAT GCG TCA AAA GTA CAG AAA AAT GGT TTT CAT AAA AAT GTG ACT GCA	969	
Ala Leu Thr Lys Asn Ile Gly Lys His Ile Asn Tyr Thr Lys Arg Gly Val Phe Phe Ser	307	
GCC CTA ACT AAA AAT ATT GGA AAG CAT ATA AAC TAT ACC AAA AGA GGA GTG TTC TTT ACT	1029	
Val Asp Ser Trp Thr Met Asp Phe Leu Ser Phe Met Tyr Lys Ser Leu Glu Arg Ser His	327	
GTG CAT TCC TCG ACC ATG GAT TCC TTA TCC TTC ATC TAC AAG TGT TTT GAG ACC AGT ATA	1089	
Arg Glu Met Phe Ile Gly Ser Ser Gln Pro Leu Thr His Val Ser Ser Pro Ala Ala Ser	347	
GCG GAG ATG TTT ATT GCG ACC TCT CAG CCA GTG ACA CAT GTT TCT ACC CCC GCA GCA TCT	1149	
Tyr Tyr Leu Ser Phe Pro Tyr Thr Arg Leu Gly Trp Ala Met Thr Ser Ala Asp Leu Asn	367	
TAC TAC TTT TCA TTT CCC TAC ACA AAG CTT GGT TGG GCA ATG ACT TCA GCT GAT CTC AAG	1209	
Gln Asp Gly Tyr Gly Asn Leu Val Val Gly Ala Pro Gly Tyr Ser His Pro Gly Arg Ile	387	
CAG GAT GGA TAC GGT CAC CTC GTG GTG GGT GCG CCT GCG TAC ACC CAC CCA GCG GCG ATT	1269	
His Val Gly Arg Val Tyr Leu Ile Tyr Gly Asn Asp Leu Gly Leu Pro Arg Ile Asp Leu	407	
CAG GTG GCG GCG GTG TAC CTC ATC TAT GCG AAT CAC CTG GCG TTT CCC CGT ATC GAC CTC	1329	
Asp Leu Asp Lys Glu Ala His Gly Ile Leu Glu Gly Phe Gln Pro Ser Gly Arg Phe Gly	427	
GAG CTG GAG AAG GAG GCG CAC GCG ATC CTG GAG GGT TTC CAG CCC TCA GGT CAA TTT GCG	1389	

FIG 5 (continued)

Ser Ala Val Ala Val Leu Asp Phe Arg Val Asp Gly Val Pro Asp Leu Ala Val Gly Arg	447
TCC GCT GTG GCT GTG CTA GAC TTT AAC GTG CAT GCG GTG GCT GAC CTG GCG GTG GGA GCG	1649
Pro Ser Val Gly Ser Glu Lys Leu Thr Tyr Thr Gly Ala Val Tyr Val Tyr Phe Gly Ser	457
CCC TCG GTG GCG TCC CAG AAG CTC ACA TAC ACA GGT GCA GTG TAT CTC TAC TTC GGT TCC	1509
Lys Glu Gly Glu Leu Ser Ser Ser Phe Asn Val Thr Ile Ser Cys Glu Asp Thr Tyr Cys	467
AAA CAA GGA CAA CTA TCT TCT TCC CCG AAC GTG ACC ATC TCT TCC CAG CAT ACC TAC TGT	1369
Asn Leu Gly Trp Thr Leu Leu Ala Ala Asp Val Asn Gly Asp Ser Glu Pro Asp Leu Val	507
AAG TTG GCG TCG ACC CTC CTC GCG GCA CAT GTG AAT GCA CAT AGT GAA CCG GAC CTC GTG	1629
Ile Gly Ser Pro Phe Ala Phe Gly Gly Gly Lys Glu Tyr Gly Ile Val Ala Ala Phe Tyr	527
ATT GCG TCC CCT TTT GCT CCA GGT GCA GGA AAA CAG AAG GCA ATT CTC GCT GCA TTT TAC	1689
Ser Gly Ser Ser Tyr Ser Ser Arg Glu Lys Leu Asn Val Glu Ala Ala Asn Trp Met Val	547
TCT GCG TCC ACT TAC AGC AGC GCA GAA AAG CTC AAT CTC CAG GCT GCG AAC TCG ATC CTC	1749
Lys Gly Glu Glu Asp Phe Ala Trp Leu Gly Tyr Ser Leu His Gly Val Asn Val Asn Asn	567
AAA GCG CAG CAG CAG TTT GCT TCG TTG GGC TAC TCC CTT CAG GGT CTC AAT CTC AAC AAC	1809
Arg Thr Leu Leu Leu Ala Gly Ser Pro Thr Trp Lys Asp Thr Ser Ser Glu Gly His Leu	587
AGG ACT TTG CTC CTC GCT CCA AGC GCG ACC TCG AAG GAC ACC AGT AAT CAG GCG CAC TTT	1869
Phe Arg Thr Arg Asp Glu Lys Glu Ser Pro Gly Arg Val Tyr Gly Tyr Phe Pro Pro Ile	607
TTC CCG ACT CCT CAT CAG AAA CAG AGC CCT GCA CCG GTG TAC GCG TAT TTC CCG CCA ATC	1929
Cys Glu Ser Trp Phe Thr Ile Ser Gly Asp Lys Ala Met Gly Lys Leu Gly Thr Ser Leu	627
TCT CAA AGC TCG TTT ACC ATT TCC GCA CAG AAG GCA ATG GAG AAA CTC GGT ACC TCC CTR	1989
Ser Ser Gly Glu Val Ile Val Asn Gly Thr Arg Thr Glu Val Leu Leu Val Gly Ala Pro	647
TCT AGT CCG CAC GTG ATG GTG AAC GCG ACC CCG ACC CAA GTG CTG CTG GTG GCG CCG CCG	2049
Thr Glu Asp Val Val Ser Lys Val Ser Phe Leu Thr Met Thr Leu His Glu Gly Gly Ser	667
ACT CAA CAT CTC CTC TCT AAG CTA TCA TTC CTC ACC ATG ACC CTG CAC CAA GAT GCG ACC	2109
Thr Arg Met Tyr Glu Leu Thr Pro Asp Ser Glu Pro Ser Leu Leu Ser Thr Phe Ser Gly	687
ACT CCG ATG TAT GAA CTC ACA CCT GAC TCA CAG CCT TCT CTC CTC ACC ACC TTC AGT GGA	2169
Asn Arg Arg Phe Ser Arg Phe Gly Gly Val Leu His Leu Ser Asp Leu Asp Asn Asp Gly	707
AAC CCG CCG TTC TCC CCA TTT GGT GCG GTT CTC CAC TTG AAT GAC TTT CAT AAT CAT GCG	2229
Leu Asp Glu Ile Ile Val His Ala Asp Pro Leu Arg Ile Thr Asp Ala Thr Ala Gly Leu Met	727
TTA GAT GAA ATC ATC GTA GCA GCG CCG CTC AGC ATC ACA CAG GCA ACT GCG GCA CTC ATG	2289
Gly Glu Glu Asp Gly Arg Val Tyr Val Phe Asn Gly Lys Glu Ile Thr Val Gly Asp Val	747
GCG GAA CAG CAT GCG GGT GTT TAT GTG TTT AAT GCG AAA CAG ATC ACC CTC GGT CAC CTC	2349
Thr Gly Lys Cys Lys Ser Trp Val Thr Pro Cys Pro Glu Glu Lys Ala Glu Tyr Val Leu	767
ACA GCG AAA TCG AAA TCA TCG GTA ACT CGT TGT CCA GAA GAA AAG GCG CAA TAT GTA CTA	2409
Ile Ser Pro Glu Ala Gly Ser Arg Phe Gly Ser Ser Val Ile Thr Val Arg Ser Lys Glu	787
ATT TCT CCT GAA GCA GCG TCA AGC TTT GCG AGC TCT CTC ATC ACT CTC ACC TCG AAG GAA	2469
Lys Asn Glu Val Ile Ile Ala Ala Gly Arg Ser Ser Leu Gly Ala Arg Leu Ser Gly Val	807
AAG AAT CAA CTC ATC ATT GCT GCT GGA AGG AAT TCT CTC GCA GCG CCA CTC TCT GCG CTC	2529
Leu His Ile Tyr Arg Leu Lys Glu Asp End	816
CTT CAT ATC TAT AGC CTC GCG CAA CAT TAA AGGTTTCACTGATTTTTC	2579

FIG 6




FIG 7




FIG 8




FIG 9

Nucleotide sequence and deduced amino acid sequence of
Human Liver GPI-Phospholipase D cDNA

```

      1
cgtcattagaggagccgggtgggggaatgagagcATGCTCTGCTTTCAGGTTGTGGCCCCGGCC
-----+-----+-----+-----+-----+-----+-----+-----+ 29
gcagtaatctcctcgggccaccccttactctcgtTACAGACGAAAGTCCAACACCGGGCCCGG
      -24
      M S A F R L W F G L -15

TGCTGATGATCGTGATGGCTTCTCTCTGCCATAGAGGTTTCATCGTGTGGCCTTTCAACGC
-----+-----+-----+-----+-----+-----+-----+-----+ 88
ACGACTACTAGCACTACCGAAGAGAGACGGTATCTCCAAGTAGCACACCGGAAAGTTGCG
      +1
      L M I V M A S L C H R G S S C G L S T H +6

ACATAGAAATCGGACACAGAGCTCTGGAGTTTCTTCATCTTCACAATGGGCATGTTAACT
-----+-----+-----+-----+-----+-----+-----+-----+ 148
TGTATCTTTAGCCTGTGTCTCGAGACCTCAAAGAAGTAGAAGTGTACCCGTACAATTGA
      +1
      I E I G H R A L E F L H L H N G H V N Y 26

ACAAAGAGCTGTTACTAGAACACCAGGATGCATATCAGGCTCGAACCCTGTTTTCTGATT
-----+-----+-----+-----+-----+-----+-----+-----+ 208
TGTTTCTCGACAATGATCTTGTGGTCTTACGTATAGTCCGACCTTGGCACAAAGGACTAA
      +1
      K E L L L E H Q D A Y Q A G T V F P D C 46

GTTTTTACCCTAGCCTCTGCAAAGGAGGAAAATTCCATGATGTGTCTGAGAGCACTCACT
-----+-----+-----+-----+-----+-----+-----+-----+ 268
CAAAAATGGGATCGGAGACGTTTCCTCCTTTTAAGGTACTACACAGACTCTCGTGAGTGA
      +1
      F Y P S L C K G G K F H D V S E S T H W 66

GGACTCCGTTTCTTAACGCAAGCGTTCATTATATCCGAGAGAACTATCCCCTTCCCTGGG
-----+-----+-----+-----+-----+-----+-----+-----+ 328
CCTGAGGCCAAAGAATTGCGTTCCGCAAGTAATATAGGCTCTCTTGATAGGGGAAGGGACCC
      +1
      T P F L N A S V H Y I R E N Y P L P W E 86

AGAAGGACACAGAGAAACTGGTAGCTTTCTTGTTTGGAAATTACTTCTCATATGCTAGCAG
-----+-----+-----+-----+-----+-----+-----+-----+ 388
TCTTCCTGTGTCTCTTTGACCATCGAAAGAACAACCTTAATGAAGAGTATACCATCGTC
      +1
      K D T E K L V A F L F G I T S H M V A D 106

```

FIG 9 (continued)

ATGTCAGCTGGCATAGTCTGGGCATTGAACAAGGATTCCTTAGGACCATGGGAGCTATTG
 -----+-----+-----+-----+-----+-----+-----+-----+ 448
 TACAGTCGACCGTATCAGACCCGTAACCTTGTTCCTAAGGAATCCTGGTACCCTCGATAAC
 V S W H S L G I E Q G F L R T M G A I D 126
 ATTTTCACGGCTCCTATTCTGAGGCTCATTTCAGCTGGTGATTTTGGAGGAGATGTGTTGA
 -----+-----+-----+-----+-----+-----+-----+-----+ 508
 TAAAAGTCCCGAGGATAAGACTCCGAGTAAGTCGACCACTAAAACCTCCTCTACACAAC
 F H G S Y S E A H S A G D F G G D V L S 146
 GCCAGTTTGAATTTAATTTTAATTACCTTGCACGACGCTGGTATGTGCCAGTCAAAGATC
 -----+-----+-----+-----+-----+-----+-----+-----+ 568
 CGGTCAAACCTTAAATTAATTAATGGAACGTGCTGCCGACCATAACCGTCAAGTTTCTAG
 Q F E F N F N Y L A R R W Y V P V K D L 166
 TGCTGGGAATTTATGAGAACTCTATGGTCCGAGAAGTCATCACTGAAAATGTAATTGTTG
 -----+-----+-----+-----+-----+-----+-----+-----+ 628
 ACGACCCCTTAAATACTCTTTGAGATACCAGCTCTTCAGTAGTGACTTTTACATTAACAAC
 L G I Y E K L Y G R E V I T E N V I V D 186
 ATTGTTCCATATCCAGTTCTTAGAAATGTATGGTGAGATGCTAGCTGTTTCCAAGTTAT
 -----+-----+-----+-----+-----+-----+-----+-----+ 688
 TAACAAGTGTATAGGTCAAGAATCTTTACATACCACTCTACGATCCGACAAAGGTTCAATA
 C S H I Q F L E M Y G E M L A V S K L Y 206
 ATCCCTCTTACTCTACAAAGTCCCGTTTTTTGGTGGAACAATCCAAGAGTATTTTCTTG
 -----+-----+-----+-----+-----+-----+-----+-----+ 748
 TAGGGAGAATGAGATGTTTCAGGGGCAAAAACCACTTGTAAAGGTTCTCATAAAAGAAC
 P S Y S T K S P F L V E Q F Q E Y F L G 226
 GAGGACTGGATGATATGGCGTTTTTGGTCCACTAATATTTACCATCTAACGAGCTTCATGT
 -----+-----+-----+-----+-----+-----+-----+-----+ 808
 CTCCTGACCTACTATACCGCAAAACCAGGTGATTATAAATGGTAGATTGCTCGAAGTACA
 G L D D M A F W S T N I Y H L T E F M L 246
 TGGAGAAATGGGACCAGTGACTGCAGCCTACCTGAGAACCCTCTGTTTCATTCATGTGGTG
 -----+-----+-----+-----+-----+-----+-----+-----+ 868
 ACCCTCTACCCCTGGTCACTGACGTGCGATGGACTCTTGGGAGACAAGTAACGTACACCAC
 E N G T S D C S L P E N P L F I A C G G 266
 GCCAGCAAAACCAACCCAGGGCTCGAAAATGCAGAAAAATGATTTTTCACAGAAATTTGA
 -----+-----+-----+-----+-----+-----+-----+-----+ 928
 CGGTCTGTTTTGGTGTGGGTCCCGAGCTTTTACGTCTTTTACTAAAAGTGTCTTTAAACT
 Q Q N H T Q G S K M Q K N D F H R N L T 286

FIG 9 (continued)

CTTCATCCCTAACTGAAAACATTGACAGGAATATAAACTATACCGAAGAGGAGTGTCTCT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 988
 GAAGTAGGGATTGACTTTTGTAAGTGTCCCTTATATTTGATATGGCTTTCTCCTCACAAGA

 S S L T E N I D R N I N Y T E R G V F F 306
 TCAGTGTAAATTCCTGGACCCCGGATTCCATGTCTTTATCTACAAGGCTTTGGAAAGGA
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1048
 AGTCACATTTAAGGACCTGGGGCCTAAGGTACAGGAAATAGATGTTCCGAAACCTTTCTCT

 S V N S W T P D S M S F I Y K A L E R N 326
 ACGTAAGGACAATGTTTCATAGGTGGCTCTCAGTTGTCCACAGAAGCACATCTCTAGCCCT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1108
 TGCATTCTCTGTTACAAGTATCCACCGAGAGTCAACAGTGTCTTCGTGTAGAGATCGGGGA

 V R T M F I G G S Q L S Q K H I S S P L 346
 TAGCATCTTACTTCTTGTCAATTTCTTATGCAAGGCTTGGCTGGGCAATGACCTCAGCTG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1168
 ATCGTAGAATGAAGAACAGTAAAGGAATACGTTCCGAACCGACCCGTTACTGGAGTCGAC

 A S Y F L S F P Y A R L G W A M T S A D 366
 ACCTCAACCAGGATGGGTACGGCCACCTCGTGGTGGGGCGCACCAGGCTACAGCCGCCCTG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1228
 TGGAGTTGGTCTTACCCATGCCGCTGGAGCACCACCCCGCTGGTCCGATGTCCGGCGGGAC

 L N Q D G Y G D L V V G A P G Y S R P G 386
 GCCGCATCCACATCGGGCGCGTGTACCTCATCTACGGCAATGAACTGGGTCTGCCGCCCCG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1288
 CGGCGTAGGTGTAGCCCGCGCACATGGAGTAGATGCCGTTACTTGACCCAGACGGCGGGG

 R I H I G R V Y L I Y G N E L G L P P V 406
 TTGACCTGGACCTGGACAAGGAGGCCACGGGATCCTTGAAGGTTTCCAGCCCTCAGGTC
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1348
 AACTGGACCTGGACCTGTTCTCCGGGTGCCCTAGGAACCTTCCAAAGGTCCGGAGTCCAG

 D L D L D K E A H G I L E G F Q P S G R 426
 GGTTTGGCTCGGCCTTGGCTATGTTGGACTTTAACATGGATGGCGTGCCTGACCTGGCCG
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1408
 CCAAACCGAGCCGGAACCGATACAACCTGAAATTGTACCTACCGCACGGACTGGACCGGC

 F G S A L A M L D F N M D G V P D L A V 446
 TGGGAGCTCCCTCGGTGGGCTCTGAGCAGCTCACCTACAAAGGTGCTGTGTATGTCTACT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 1468
 ACCCTCGAGGGAGCCACCCGAGACTCGTGGAGTGGATGTTTCCACGACACATACAGATGA

 G A P S V G S E Q L T Y K G A V Y V Y F 466

FIG 9 (continued)

```

TGGGTTCCAAACAAGGAAGAATGTCTTCTTCCCCTAACATCACCATCTCTTGCCAGGACA
-----+-----+-----+-----+-----+-----+-----+-----+ 1528
AACCAAGGTTTGTTCCTTCTTACAGACAGAGCGGATTGTAGTGGTAGAGAACGGTCCTGT
G S K Q G R M S S S P N I T I S C Q D I 486

TACTGTAACTTGGGCTGGACTCTCTTGGCTGCAGATGTGAATGGAGACAGTGAGCCCCG
-----+-----+-----+-----+-----+-----+-----+-----+ 1588
ATGACATTGAACCCGACCTGAGAGAACCGACGTCTACACTTACCTCTGTCACTCGGGC
Y C N L G W T L L A A D V N G D S E P D 506

TGTGGTCATTGGCTCCCCCTTTTGCACCAGGTGGAGGGAAGCAGAAGGGAATTGTGGCTG
-----+-----+-----+-----+-----+-----+-----+-----+ 1648
TAGACCAGTAACCGAGGGGAAAACGTGGTCCACCTCCCTTCGTCTTCCCTTAACACCGAC
L V I G S P F A P G G G K Q K G I V A A 526

TTTTTATTCTGGCCCCAGCCTGAGCAACAAGAGAAACTGAACGTGGAGCGGGCCAACT
-----+-----+-----+-----+-----+-----+-----+-----+ 1708
CAAAATAAGACCGGGGTGGACTCGTTGTTTCTCTTTGACTTGCACCTCCGCGGGTTGA
F Y S G P S L S N K E K L N V E A A N W 546

ACGGTGAGAGGCGAGGAAGACTTTGCCTGGTTTGGATACTCCCTTCACGGTGTCACTG
-----+-----+-----+-----+-----+-----+-----+-----+ 1768
TGCCACTCTCCGCTCCTTCTGAAACGGACCAAACCTATGAGGGAAGTGCCACAGTGAC
T V R G E E D F A W F G Y S L H G V T V 566

GACACAGAACCTTGCTGCTGGTTGGGAGCCCGACCTGGAAGAATGCCAGCAGGCTGG
-----+-----+-----+-----+-----+-----+-----+-----+ 1828
ACTGTTGTCTTGGAAACGACGACCAACCCCTCGGGCTGGACCTTCTTACGGTCTGTCGACC
D N R T L L L V G S P T W R N A S R L G 586

CGTTTGTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGGGTGTATGGCTACTTCC
-----+-----+-----+-----+-----+-----+-----+-----+ 1888
CGCAAACAATGTGTAGGCTCTACTCTTTTCTCGGAACCCCTCCACATACCGATGAAGG
R L L H I R D E K K S L G R V Y G Y F P 606

CCCAAACAGCCAAAGCTGGTTTACCATTGTTGGAGACAAGGCAATGGGGAAACTGGGTA
-----+-----+-----+-----+-----+-----+-----+-----+ 1948
TGGTTTGTGCGTTTTCGACCAATGGTAAACACCTCTGTTCCGTTACCCCTTTGACCCAT
P N S Q S W F T I V G D K A M G K L G T 626

TTCCTTGTCAGTGGCCACCTGCTGATGAATGGAACCTCTGACCCAGGTGCTGCTGGTG
-----+-----+-----+-----+-----+-----+-----+-----+ 2008
GAAGGGACAGGTCACCGGTGCACGACTACTTACCTTGAGACTGGGTCCACGACGACCACC
S L S S G H V L M N G T L T Q V L L V G 646

```

FIG 9 (continued)

GAGCCCCGACACGTGATCATGTGTCTAAGATGGCATTCCCTGACCATGACCCTGCACCAAG
 -----+-----+-----+-----+-----+-----+-----+ 2068
 CTCGGGGCTGTGCACTACTACACAGATTCTACCGTAAGGACTGGTACTGGGACGTGGTTC
 A P T R D D V S K M A F L T M T L H Q G 556
 GCGGAGCCACTCGGATGTACGCGCTCACATCCGACCTGCAGCCACCGCTGCTCAGCACCT
 -----+-----+-----+-----+-----+-----+-----+ 2128
 CGCCTCGGTGAGCCTACATGCGCGAGTGTAGGCTGGACGTCCGTGGCGACGAGTCCGTGGA
 G A T R M Y A L T S D L Q P P L L S T F 686
 TCAGCGGAGACCGCCGCTTCTCTCGATTGTTGGTGGCGTTCTGCACTTGAGTGACCTGGATG
 -----+-----+-----+-----+-----+-----+-----+ 2188
 AGTCGCCCTCTGGCGCGCAAGAGAGCTAAACCCGCAAGACCTGAACCTCACTGGACCTAC
 S G D R R F S R F G G V L H L S D L D D 706
 ATGATGGCGTAGATGAAATCATCGTGGCAGCCCCCTGAGGATAGCAGATGTAACCTCTG
 -----+-----+-----+-----+-----+-----+-----+ 2248
 TACTACCGCATCTACTTTAGTAGCACCGTCCGGGGGACTCCTATCGTCTACATTGGAGAC
 D G V D E I I V A A P L R I A D V T S G 726
 GGCTGATTGGGGGAGAAGATGGCCGAGTTTATGTATATAATGGCAAAGAGACCACCCTTG
 -----+-----+-----+-----+-----+-----+-----+ 2308
 CCGACTAAACCCCTCTTCTACCGGCTCAAATACATATATTACCGTTTCTCTGGTGGGAAC
 L I G G E D G R V Y V Y N G K E T T L G 746
 GTGACATGACTGGCAATGCAAATCGTGGATGACTCCATGTCCAGAAGAAAAGGCCCAAT
 -----+-----+-----+-----+-----+-----+-----+ 2368
 CACTGTACTGACCGTTTACGTTTAGCACCTACTGAGGTACAGGTCTTCTTTTCCGGGTTA
 D M T G K C K S W M T P C P E E K A Q Y 766
 ATGTATTGATTTCTCCTGAAGCCAGCTCAAGGTTTGGGAGCTCCCTGATCACCGTGAGGT
 -----+-----+-----+-----+-----+-----+-----+ 2428
 TACATAACTAAAGAGGACTTCGGTGGAGTTCCAAACCCCTCGAGGGACTAGTGGCACTCCA
 V L I S P E A S S R P G S S L I T V R S 786
 CCAAGGCAGAAGATCAAGTCGTCATTGCCGCTGGAAGGAGCTCTTTGGGAGCCCGACTCT
 -----+-----+-----+-----+-----+-----+-----+ 2488
 GGTTCGGTTTCTTAGTTTACGCACTAAACGCGACCTTCCTCGAGAAACCTCGGGCTGAGA
 K A K N Q V V I A A G R S S L G A R L S 806
 CCGGGGCACCTTCACGTCTATAGCCTTGGCTCAGATTGA
 -----+-----+-----+-----+-----+-----+-----+ 2526
 GGCCCCGTGAAGTGCAGATATCGGAACCGAGTCTAACT

FIG 10

Alignment of deduced amino acid sequence of
Human and Bovine Liver GPI-Phospholipase D

	-24					25
Bovine	MSAFRFWSGL	LMLL.GFLCP	RSSP.CGIST	HIEIGHRALE	FLHLQDGSIN	
Human	MSAFRLWPGL	LMIVMASLCH	RGSS.CGLST	HIEIGHRALE	FLHLNNGHVN	
	MSAFR.W.GL	LM.....LC.	R.S...CG.ST	HIEIGHRALE	FLHL..G..N	
	26					75
Bovine	YKELLRLHQD	AYQAGSVFPD	SFYPsicERG	QFHDVSESTH	WTPFLNASVH	
Human	YKELLLEHQD	AYQAGTVFPD	CFYPSLCKGG	KFHDVSESTH	WTPFLNASVH	
	YKELL..HQD	AYQAG.VFPD	.FYPS.C..G	.FHDVSESTH	WTPFLNASVH	
	76					125
Bovine	YIRKNYPLPW	DEDTEKLVAF	LFGITSHMVA	DVNWWSLGIE	QGFLRTMAAI	
Human	YIRENYPLPW	EKDTEKLVAF	LFGITSHMVA	DVSWWSLGIE	QGFLRTMGAI	
	YIR..NYPLPW	..DTEKLVAF	LFGITSHMVA	DV..WSLSGIE	QGFLRTM..AI	
	136					175
Bovine	DFHNSYPEAH	PAGDFGGDVL	SQPEFKFNYL	SRHWYVPAED	LLGIYRELYG	
Human	DFHGSYSEAH	SAGDFGGDVL	SQFEFNFNYL	ARRWYVPVKD	LLGIYEXLYG	
	DFH..SY..EAH	.AGDFGGDVL	SQFEF..FNYL	.R.WYVP...D	LLGIY...LYG	
	176					225
Bovine	RIVITKKAIV	DCSYLQFLEV	YAEMLAISKL	YPTYSVKSPF	LVEQFQEYFL	
Human	REVITENVIV	DCSHIQFLEM	YGEMLAVSKL	YPSYSTKSPF	LVEQFQEYFL	
	R.VIT...IV	DCS...QFLE.	Y..EMLA..SKL	YP..YS..KSPF	LVEQFQEYFL	
	226					275
Bovine	GGLDMAFWWS	TNIYHLTSYM	LKNGTENCNL	PENPLFITCG	GQQNNTGSGK	
Human	GGLDOMAFWS	TNIYHLTSFM	LENGTSDCSL	PENPLFIACG	GQQNHTQSGK	
	GGL..OMAFWS	TNIYHLTS..M	L..NGTS..C..L	PENPLFI..CG	GQQN..T..GSK	
	276					325
Bovine	VQKNGFHKNV	TAALTGNIGK	HINYTKRGVF	FSVDSWTMDS	LSPMYKSLER	
Human	MQKNDFHRNL	TSSLTENIDR	NINYTERGVF	FSVNSWTEDS	MSFIYKALER	
	.QKN..FH..N.	T...LT..NI..	..INYT..RGVF	FSV..SWT..DS	..SP..YK..LER	
	326					375
Bovine	SIREMFIGSS	Q..PLTHVSSP	AASYLSFPY	TRLGWAMTSA	DLNQDGYGDL	
Human	NVRTMFIGGS	QLSQKHISSP	LASYFLSFPY	ARLGWAMTSA	DLNQDGYGDL	
	..R..MFIG..S	Q....H..SSP	..ASY..LSFPY	..RLGWAMTSA	DLNQDGYGDL	
	376					425
Bovine	VVGAPGYSHF	GRIHVG RVYL	IYGN DLGLPR	IDLDLDKEAH	GILEGFQPSG	
Human	VVGAPGYSRP	GRIHIG RVYL	IYGN ELGLPP	VDLDLDKEAH	GILEGFQPSG	
	VVGAPGYS..P	GRIH..GRVYL	IYGN..LGLP.	..DLDLDEAH	GILEGFQPSG	

FIG 10 (continued)


Bovine	426	RFGSAVAVLD	FNVDGVFDLA	VGAPSVGSEX	LTYTGAVYVY	FGSKQGQLSS	475
Human		RFGSALAMLD	FNMDGVFDLA	VGAPSVGSEQ	LTYKGAVYVY	FGSKQGRMSS	
		RFGSA.A.LD	FN.DGVFDLA	VGAPSVGSE.	LTY.GAVYVY	FGSKQG..SS	
Bovine	476	SPNVTISCQD	TYCNLGWTL	AADVNGDSEP	DLVIGSPFAP	GGGKQKGIVA	525
Human		SPNITISCQD	IYCNLGWTL	AADVNGDSEP	DLVIGSPFAP	GGGKQKGIVA	
		SPN.TISCQD	.YCNLGWTL	AADVNGDSEP	DLVIGSPFAP	GGGKQKGIVA	
Bovine	526	AFYSGSSYSS	REKLNVEAAN	WMVKGEEDFA	WLGYSILHGVN	VNNRTLLLAG	575
Human		AFYSGPSLSN	KEKLNVEAAN	WTVRGEEDFA	WFGYSILHCVT	VDNRTLLLVG	
		AFYSG.S.S.	.EKLNVEAAN	W.V.GEEDFA	W.GYSILHGV.	V.NRTLLL.G	
Bovine	576	SPTWKDTSSQ	GHLFETRDEK	QSPGRVYGYF	PPICQSWFTI	SGDKAMGKLG	625
Human		SPTWKNASRL	GRLLRHIRDEK	KSLGRVYGYF	PPNSQSWFTI	VGDKAMGKLG	
		SPTWK..S..	G.L...RDEK	.S.GRVYGYF	PP..QSWFTI	.GDKAMGKLG	
Bovine	626	TSLSSGHVMV	NGTRTQVLLV	GAPTQDVVSK	VSFLTMTLHQ	GGSTRMYELT	675
Human		TSLSSGHVLM	NGTLTQVLLV	GAPTRDDVSK	MAFLTMTLHQ	GGATRMXYALT	
		TSLSSGHV..	NGT.TQVLLV	GAPT.D.VSK	..FLTMTLHQ	GG.TRMXY.LT	
Bovine	676	PDSQPSLLST	FSGNRRFSRF	GGVLHLSDLQ	NDGLDEIIVA	APLRITDATA	725
Human		SDLQPPLLST	FSGDRRFSRF	GGVLHLSDLQ	DDGVDEIIVA	APLRIADVTS	
		.D.QP.LLST	FSG.RRFSRF	GGVLHLSDLQ	.DG.DEIIVA	APLRI.D.T.	
Bovine	726	GLMGEEDGRV	YVFNGKQITV	GDVTGKCKSW	VTPCPPEEKAQ	YVLISPEAGS	775
Human		GLIGGEDGRV	YVYNGKETTL	GDMTGKCKSW	MTPCPPEEKAQ	YVLISPEASS	
		GL.G.EDGRV	YV.NGK..T.	GD.TGKCKSW	.TPCPPEEKAQ	YVLISPEA.S	
Bovine	776	RFGSSVITVR	SKEKNQVIIA	AGRSSLGARL	SGVLHIYRLG	QD*	B17
Human		RFGSSLITVR	SKAKNQVVIA	AGRSSLGARL	SGALHVYSLG	SD*	
		RFGSS.ITVR	SK.KNQV.IA	AGRSSLGARL	SG.LH.Y.LG	.D*	

FIG 11

The Nucleotide Sequence and Amino Acid Sequence of the Human
Pancreatic Glycosyl Phosphatidyl Inositol Specific-Phospholipase D.

1	GACAGTGAACCCGATCTGCTCATCGGCTCCCTTTTGCACCAGGTGGAGGGAAGCAGAAAG	60
1	AspSerGluProAspLeuValIleGlySerProPheAlaProGlyGlyGlyLysGlnLys	20
61	GGATTGTGGCTGCTTTTATTCTGGGCCCCAGCCTGAGCGACAAAGGAAAACTGACGCTG	120
21	GlyIleValAlaAlaPheTyrSerGlyProSerLeuSerAspLysGluLysLeuAsnVal	40
121	GAGGACAGCCAACTGGACGGTGGAGAGGCGAGCAAGACTTCTGCTGGTTTGGATATTCCCTT	180
41	GluAlaAlaAsnTrpThrValArgGlyGluGluAspPheSerTrpPheGlyTyrSerLeu	60
181	CAGGGTGTCACTGTGGACAAACAGAACCTTGTCTTGGTTGGGAGGCCGACCTGGAAGGAT	240
61	HisGlyValThrValAspAsnArgThrLeuLeuLeuValGlySerProThrTrpLysAsn	80
241	GCGAGCAGGCTGGGCGATTTTGTACACATCCGAGATGAGAAAAAGAGCCTTGGGAGGGTG	300
81	AlaSerArgLeuGlyHisLeuLeuHisIleArgAspGluLysLysSerLeuGlyArgVal	100
301	TATGGCTACTTCCGACCAACCGGCCAAGCTGCTTACCATTTCTGGAGACAAAGCCATG	360
101	TyrGlyTyrPheProProAsnGlyGlnSerTrpPheThrIleSerGlyAspLysAlaMet	120
361	GGGAAACTGGGTACTTCCCTTTCCAGTGGCTCAGTACTGATGAATGGGACTCTGAAACAA	420
121	GlyLysLeuGlyThrSerLeuSerSerGlyHisValLeuMetAsnGlyThrLeuLysGln	140
421	GTGCTGCTGGT7GGAGCCCTACGTACGATGACBTGTCTAAGGTGGCATTCCTGACCGTG	480
141	ValLeuLeuValGlyAlaProThrTyrAspAspValSerLysValAlaPheLeuThrVal	160
481	ACCTTACACCAAGGCGGAGCCACTCGGTGTACGCACTCATATCTGACGGCGAGCCTCTG	540
161	ThrLeuHisGlnGlyGlyAlaThrArgValTyrAlaLeuIleSerAspAlaGlnProLeu	180
541	CTGCTCAGCAGCCTTCAGCGGAGACCGGCCCTTCTCCCGATTGGTGGCCTTCTGCACTTG	600
181	LeuLeuSerThrPheSerGlyAspArgArgPheSerArgPheGlyGlyValLeuHisLeu	200
601	AGTGACCTGGATEATGATGGCTTAGATGAATCATCATGAGCGCCCGCCTGAGGATAGCA	660
201	SerAspLeuAspAspAspGlyLeuAspGluIleIleMetAlaAlaProLeuArgIleAla	220
661	GATGTAACTCTGGACTGATTGGGGBAGAGAGACGCCCCAGTATATGTATATATGTCGAAA	720
221	AspValThrSerGlyLeuIleGlyGlyGluAspGlyArgValTyrValTyrAsnGlyLys	240
721	GAGACCAACCTTGGTGACATGACTGGCAATGCAATCATGATAGCTCCATGTCCAGAA	780
241	GluThrThrLeuGlyAspMetThrGlyLysDysLysSerTrpIleThrProCysProGlu	260
781	GAAAGGCGCAATATGTATTGATTCTCTGAGGCCAGCTCAAGGTTTGAGGCTCCCTC	840
261	GluLysAlaGlnTyrValLeuIleSerProGluAlaSerSerArgPheGlySerSerLeu	280
841	ATCACCTGAGGTCCAAAGGCAAGAACCAAGTCCTCATTTGCTGCTGGAAGGAGTTCTTTG	900
281	IleThrValArgSerLysAlaLysAsnGlnValValIleAlaAlaGlyArgSerSerLeu	300
901	GGAGCCCGACTCTCCGGGSCACTTCACBTCTATAGCCCTTGCTCAGATTGAAGATTTGAC	960
301	GlyAlaArgLeuSerGlyAlaLeuHisValTyrSerLeuGlySerAsp	320
961	TGATTTCCCGACTCTGCCCACTCTCTCATGCTGAATCAGATCCATGGTGAGCATTTTG	1020
1021	ATGACAAAGTGGCACATCCAGTGGAGCGGTGGTAGATCTGTATAGACATGGGGCTCTGTG	1080
1081	GGAGTAGAGAGACACACTAACAGGCGACACCCCTCTGGAAATCTGATACAGTAAATATATGA	1140
1141	CTACACCGAGAAATATGTGAATAGCAGACATTCTGCTTACTCATGTCTCCTTCCACAGTT	1200
1201	TACTTCTGCTGCTCCCTTTTGCATCTAAAGCTTCTTCTTTCCCACTTAT7GCTGTAGTC	1260

FIG 12



(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 477 739 A3

(12)

EUROPEAN PATENT APPLICATION(21) Application number: **91115787.3**

(51) Int. Cl.⁵: **C12N 15/55, C12N 9/16,
C12P 21/02, C12P 21/08,
A61K 39/395**

(22) Date of filing: **18.09.91**(30) Priority: **27.09.90 US 588896**

(43) Date of publication of application:
01.04.92 Bulletin 92/14

(84) Designated Contracting States:
AT BE CH DE DK FR GB IT LI NL

(88) Date of deferred publication of the search report:
09.12.92 Bulletin 92/50

(71) Applicant: **F. HOFFMANN-LA ROCHE AG
Postfach 3255
CH-4002 Basel(CH)**

(72) Inventor: **Huang, Kuo-Sen
38 Intervale Road
Livingston, N.J. 70039(US)
Inventor: Kochan, Jarema Peter
7 Crestmont Road
Verona, N.J. 07044(US)
Inventor: Li, Shirley Hsia-Han
969 Bloomfield Avenue
Glen Ridge, N.J. 07028(US)
Inventor: Pan, Yu-Ching Eugene
10 Crane Drive
Pine Brook, N.J. 07058(US)
Inventor: Scallon, Bernard James
500 Center Street
Nutley, N.J. 07110(US)
Inventor: Tsang, Thomas Christopher
Hin-Sing
468 De Witt Avenue
Belleville, N.J. 07109(US)**

(74) Representative: **Mezger, Wolfgang, Dr. et al
Grenzacherstrasse 124 Postfach 3255
CH-4002 Basel(CH)**

(54) **Glycosyl-Phosphatidylinositol-Specific Phospholipase D.**

(57) The present invention relates to the protein glycosyl phosphatidylinositol-specific phospholipase D (GPI-PLD) in a substantially pure form, an polynucleotide coding for GPI-PLD, vectors containing the isolated polynucleotide coding for GPI-PLD, and cells transformed by a vector containing the polynucleotide coding for GPI-PLD. Also described is a method for producing a protein which can be secreted from a eukaryotic cell comprising co-transfecting a eukaryotic cell with a gene encoding a glycosyl phosphatidylinositol-anchored protein with

glycosyl phosphatidylinositol-specific phospholipase D.

EP 0 477 739 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 11 5787

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	THE FASEB JOURNAL, (Abstracts: American Society for Biochemistry and Molecular Biology, The American Association of Immunologists Joint Meeting, New Orleans, Louisiana, 4th - 7th June 1990), vol. 4, no. 7, 26th April 1990, page A1775, abstract no. 474, Bethesda, US; W.-J. FUNG et al.: "Purification of glycosyl phosphatidylinositol-specific phospholipase D by immunoaffinity chromatography" * Abstract *	1-4, 9-17, 22	C 12 N 15/55 C 12 N 9/16 C 12 P 21/02 C 12 P 21/08 A 61 K 39/395
Y	IDEM ---	5-8, 18-20, 21	TECHNICAL FIELDS SEARCHED (Int. Cl.5) C 12 N
D, Y	PROC. NATL. ACAD. SCI. OF USA, vol. 85, February 1988, pages 980-984, Washington, DC, US; M.G. LOW et al.: "A phospholipase D specific for the phosphatidylinositol anchor of cell-surface proteins is abundant in plasma" * Whole document *	5-8, 21, 22	
A	IDEM ---	1-4, 9-17	
Y	EP-A-0 319 944 (ZYMOGENETICS INC.)(14-06-1989) * Abstract; page 2, last paragraph - page 3, paragraph 1.* --- -/-	18-20	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 17-09-1992	Examiner VAN DER SCHAAL C.A.M.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 01/87 (P0401)



European Patent
Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid,
namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions,

namely:

see sheet -B-

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid,
namely claims:
- ☐ None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims,
namely claims:



European Patent
Office

EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 91 11 5787

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)	
D,Y	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 150, no. 1, 15th January 1988, pages 476-482; M.L. GARDOSO DE ALMEIDA et al.: "Identification of an acid-lipase in human serum which is capable of solubilizing glycoposphatidylinositol-anchored proteins" * Whole document *	21		
Y	PROC. NATL. ACAD. SCI. OF USA, vol. 85, no. 23, December 1988, pages 8914-8918, Washington, DC, US; D. HERELD et al.: "cDNA encoding the glycosyl-phosphatidylinositol-specific phospholipase C of trypanosoma brucei" * Whole document *	21		
A	IDEM	12-17, 22		TECHNICAL FIELDS SEARCHED (Int. Cl.5)
O,X	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 29, 15th October 1990, pages 17738-17745, (Partially presented at the 81st annual meeting of the Am. Soc. Biochim. and Mol. Biol., 3rd - 7th June 1990), K.-S. HUANG et al.: "Purification and characterization of glycosyl-phosphatidylinositol-specific phospholipase D" * Whole document *	1-17,22		
Y	IDEM	18-21		
The present search report has been drawn up for all claims				
Place of search THE HAGUE		Date of completion of the search 17-09-1992	Examiner VAN DER SCHAAL C.A.M.	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document				

EPO FORM 1503 03.92 (P0401)



European Patent
Office

EUROPEAN SEARCH REPORT

Page 3

Application Number

EP 91 11 5787

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
P, X	SCIENCE, vol. 252, 19th April 1991, pages 446-448; B.J. SCALLON et al.: "Primary structure and functional activity of a phosphatidylinositol-glycan-specific phospholipase D" * Whole document *	1-17, 22	
Y	IDEM -----	18-21	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 17-09-1992	Examiner VAN DER SCHAAL C.A.M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P0401)



European Patent
Office

EP 91 11 5987 -B-

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-20 purified GPI-Phospholipase D, polynucleotide coding for this protein and use of the polynucleotide
2. Claim : 21 use of GPI-PLD for cleaving proteins
3. Claim : 22 antibodies against GPI-PLD